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        Cancer therapy and tumor treatment remain unsolved puzzles. Genetic screening 
for tumor suppressor genes in Drosophila revealed the Hippo-signaling pathway as a 
kinase cascade consisting of five core components. Disrupting the pathway by deleting 
the main component genes breaks the balance of cell proliferation and apoptosis and 
results in epithelial tissue tumorigenesis. The pathway is therefore believed to be a 
tumor suppressor pathway. However, a corresponding role in mammals is yet to be 
determined. Our lab began to investigate the tumor suppression function of the potent 
mammalian Hippo pathway by putting floxed alleles into the mouse genome flanking 
the functional-domain-expressing exons in each component (Mst1, Mst2, Sav1, Lats1 
and Lats2). These mice were then crossed with different cre-mouse lines to generate 
conditional knockout mice. Results indicate a ubiquitous tumor suppression function of 
these components, predominantly in the liver. A further liver specific analysis of the 
deletion mutation of these components, as well as the Yap/Taz double deletion 
mutation, reveals essential roles of the Hippo pathway in regulating hepatic 
quiescence and embryonic liver development. One of the key cellular mechanisms for 
the Hippo pathway’s involvement in these liver biological events is likely its cell cycle 
regulation function. Our work will help to develop potential therapeutic approaches for 
liver cancer.  
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CHAPTER 1: BACKGROUND 
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  Genetic alteration can cause many human diseases, including developmental 
defects in fetus and tumor development in adults. In searching for cures, scientists 
have stepped into a long journey of unveiling disease mechanisms starting from 
identifying genes that are important for organ development and tissue homeostasis. 
These are the two main topics being pursued for decades. With the advances of 
research techniques and the discoveries of genetic modification tools, high-throughput 
genetic analysis has been established and many genes and pathways essential for 
organ development and tissue homeostasis have been identified, one of which is the 
Hippo pathway.  
 At the time we started our project, our knowledge about the Hippo pathway is 
limited to Drosophila animal model and the in vitro biochemical interactions between 
the mammalian components. For the Hippo pathway’s function in the mammalian 
system, although biochemical studies provided valuable information on protein-protein 
interactions, they have limitations in addressing how these Hippo pathway main 
components function in a true biological environment and how they contribute to the 
development or homeostasis of an organ or an animal as a whole. We therefore 
generated genetically engineered mouse models of the main components, and started 
to investigate the Hippo pathway’s in vivo function in several organs. We later focused 
our study on mouse liver because our preliminary data indicated a certain tissue-
specificity of the Hippo pathway in liver. We found that deregulation of the Hippo 
pathway affected several important aspects of the liver, including inflammatory 
response, liver stem cell activation, liver development, and liver regeneration. Our 
study will help understand the Hippo pathway’s tumor suppressor function in 
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mammals, and may put new insights into the cancer treatments, especially to the liver 
cancer treatments.  
1.1 Drosophila Hippo pathway 
The Hippo signaling pathway was originally identified in Drosophila by genetic 
screening for genes involved in cell growth and proliferation. The first identified 
pathway component is Wts, whose deletion results in cell autonomous proliferation 
and epithelium over growth [1,2]. Warts (Wts) is named for a phenotype in which 
mutated cells proliferate dramatically in imaginal discs and grow into wart-like mitotic 
clones on adult. Other pathway components were subsequently identified by similar 
phenotypes after gene deletion in imaginal discs. These components are: Ste20-like 
protein kinase Hpo, WW domain-containing protein Sav, and the adaptor protein Mats 
[2,3,4,5,6,7,8,9]. Biochemical studies further put them together as a kinase cassette 
(Hpo/Sav1/Mats/Wts): Hpo phosphorylates and activates Wts [8] in the presence of 
Sav and Mats that act as scaffolding proteins to facilitate the interaction between Hpo 
and Wts. Hpo and Wts are both Ser/Ter kinases capable of being activated by 
autophosphorylation [10,11], although Wts activation can also be regulated by Hpo 
phosphorylation. Hpo can also phosphorylate Sav and Mats [8,9], which further 
facilitates Wts binding and activation. The sequential phosphorylation and activation of 
the Hippo pathway components explains the similarity and also the progressive 
severity of mutant phenotypes. Deletion of downstream component (Wts) results in a 
similar but more severe phenotype than that of an upstream component (Hpo or Sav).  
Hpo/Sav/Mats/Wts is the core kinase cassette of the Hippo pathway. It functions to 
sense and mediate extracellular signal transduction to the cell nuclei. Although it is yet 
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unknown what the extracellular signals are in a normal tissue context, some 
intracellular regulators upstream of Hpo/Sav1/Mats/Wts kinase cassette have been 
identified, such as Mer-Ex-Kibra complex [12,13,14,15], Fat signaling [16,17,18,19,20], 
and Lethal giant larvae (Lgl) complex [21]. Among these regulators, the Mer-Ex-Kibra 
complex is the most important, as it activates the Hippo pathway through both Hpo 
and Wts phosphorylation. Mer, Ex and Kibra function redundantly in regulating Hippo 
signaling pathway and each one can function independent of the others. In the case of 
cell-cell contact inhibition, cell will stop growing when the Hippo pathway is activated 
by Ex, which is activated by binding with the transmembrane protein Crb upon its 
homodimerization between two adjacent cells [22]. This is one of the mechanisms by 
which the Hippo pathway regulates cell growth.  
Although the Hpo/Sav1/Mats/Wts kinase cassette functions to suppress tissue 
growth, none of them is a nuclear transcription factor. By yeast two-hybrid screening, 
the nuclear transcriptional cofactor Yki was identified and has been demonstrated to 
be a dominant Wts-binding protein. Activated Wts can phosphorylate Yki, and this 
phosphorylation enables the binding of an adaptor protein, 14-3-3, with Yki, which is 
then followed by Yki cytoplasmic tethering and functional suppression [23,24,25]. 
While nuclear-cytoplasmic translocation is believed to be the main mechanism of 
regulation for Yki function, there is also evidence that Wts can inhibit Yki through 
physical binding [23]. This finding further explains why the Wts deletion has the most 
severe phenotype compared to the deletion phenotypes of other the Hippo pathway 
components. Yki activity can also be suppressed by direct protein-protein binding 
between its WW-domains and the proline-rich sequences within PPXY motifs. This is 
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evidenced by Yki inhibition in association with Ex, Kibra, Hpo or Wts [26,27], all of 
which have the PPXY motifs. Although several Hippo pathway upstream regulators 
have been identified, Yki is so far the only known nuclear effecter of the Drosophila 
Hippo kinase cassette that bridges the cytoplamic Hpo/Sav1/Mats/Wts kinase cassette 
with nuclear target gene transcription.   
Yki itself lacks a DNA binding domain. It has to associate with DNA-binding 
proteins to execute its gene transcription regulation function. Several associated 
transcription factors have been identified, such as Sd (initiates diap1 gene expression) 
[28,29], Mad [30] and Hth [31] (for ban expression). dE2F1 can also associate with Yki 
and function synergistically with the Yki/Sd complex in promoting G1-to-S phase cell 
cycle progression [32]. This supports the notion that the Hippo pathway regulates cell 
cycle and proliferation and thus controls tissue growth.  
In summary, Hpo/Sav1/Wts/Mats kinase cassette mediates signal transduction of 
extracellular stimuli down to the nuclear transcription cofactor Yki. The diverse 
transcription factor binding ability of Yki enables the Hippo pathway to function in 
multiple biological processes. The observations that deletion of any component in 
Hpo/Sav/Wts/Mats cassette or over-expression of Yki results in tissue over-growth and 
organ enlargement suggests that the Hippo pathway plays fundamental roles during 
organ size control and may also be a suppressing pathway during tumorigenesis, an 
uncontrolled cell proliferation process (Diagram 1).  
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Diagram 1. Drosophila Hippo pathway. Hpo kinase is activated by Mer/Ex/Kibra 
complex). Activated Hpo kinase phosphorylates and activates kinase Wts, which is 
facilitated by Sav adaptor protein. Activated Wts, with another helper protein Mats, 
phosphorylates the nuclear transcription cofactor Yki. This phosphorylation, however, 
inhibits Yki function. Unphosphorylated Yki will associate with transcription factors, 
such as Sd, to initiate target-gene expression, some of which are known to be pro-
proliferation and against apoptosis.  
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1.2    Mammalian counterparts of the Hippo pathway components.  
The Hippo pathway is evolutionarily conserved. Many core components exist 
across species, including yeast, flies, rodents, and Homo sapiens. Most mammalian 
counterparts have functionally redundant paralogs as shown in Table 1. Biochemical 
interactions among mammalian counterparts are similar to those in Drosophila 
(Diagram 2) [8,9,23,33,34,35]. Briefly, Mst phosphorylates and activates Lats which 
further phosphorylates Yap/Taz. Phosphorylated Yap/Taz binds to adaptor protein 14-
3-3 and is exported from the nucleus [35]. Sav1 and Mob1 function to facilitate the 
interaction between Mst and Lats.   
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Table1. Mammalian counterparts of the Hippo pathway core components 
Drosophila Mouse/Human References 
Mst1 
Hpo  
Mst2 
[36,37,38,39,40,41] 
Sav WW45/Sav1 [42] 
Lats1 
Warts 
Lats2 
[43,44] 
Mats Mob1 [45,46,47] 
Yap 
Yki 
Taz/WWTR1 
[34,48,49,50,51] 
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Diagram 2. Biochemical interactions between the mammalian Hippo pathway 
components. Lats1/2 (Wts orthologs) can be activated through phosphorylation by 
Mst1/2 and Kibra/NF2 (Mer ortholog) complex, both of which are facilitated by the 
adaptor protein Sav1 (Sav ortholog). Activated Lats1/2 further phosphorylates but 
inhibits Yap/Taz (Yki ortholog), which is facilitated by another adaptor protein Mob1. 
Unphosphorylated Yap/Taz associates with the transcription factor TEAD and initiates 
the target gene expression, such as ctgf.  
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         Mst1 and Mst2 are Ste20-like kinases that ubiquitously expressed. The C-
terminal SARAH domain mediates Mst1 and Mst2 self-binding and also binding with 
other SARAH-containing proteins such as Sav1 and Nore1 (a member of the Rassf 
tumor suppressor family). The Mst /Sav1 complex functions as mammalian Hippo 
signaling that inhibits growth. Mst/Nore1 complex plays an important role during T-cell 
development. Mst inhibitory effect on cell growth and survival is also represented by its 
involvement in stress-induced cell apoptosis, during which Mst is activated by 
caspase-dependent cleavage into a 36 kDa protein kinase which translocates from the 
cytosol to the nucleus where it contributes to chromatin condensation during apoptosis 
[52]. Overall, Msts exert a negative effect on cell growth and survival. 
        Lats belongs to the NDR/Lats kinase family and was known to be a tumor 
suppressor before it was related with the Hippo pathway. Lats expresses ubiquitously 
and plays essential roles in various cellular events such as proliferation, cytoskeletal 
dynamics, cell migration, mitotic exit, transcriptional regulation and genetic 
maintenance of stability maintenance [53]. The multiple functions rely on its protein 
structure, which contains a protein-binding domain (PBD), a catalytic domain, two Lats 
conserved domains (LCD), and PPxY motifs. Lats potentially interacts with multiple 
cellular regulators and is thought to be a broad governor for cellular homeostasis. 
However, so far Yap and Taz are the only two identified substrates of Lats.  
        Sav1 (also named WW45) and Mob1 are scaffold proteins that facilitate 
interaction between Mst-Lats and Lats-Yap/Taz, respectively. Sav1 biochemically 
binds to Mst1, Mst2 and Rassf1 [54,55]. It has two WW-domains, which can bind to 
PPXY motifs within other proteins including Lats and Yap/Taz. Evidence shows that 
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NF2 (Mer ortholog) together with mammalian Kibra can phosphorylate and activate 
Lats by binding with Sav1 [56]. Therefore, functions of mammalian Sav1 are thought to 
be very similar to its Drosophila ortholog. Mob1 is known to be required for the 
abscission of the midbody during cytokinesis. Other than this, little is known about 
Mob1.  
        Both Yap and Taz are mammalian orthologs of Yki, with Yap being more 
structurally similar to Yki. Yap has two WW-domains while Taz has only one [57]. Taz 
lacks an SH3-domain, which is present in Yap. The structural difference suggests that 
Yap but not Taz may be the predominant effecter of the mammalian Hippo pathway. 
Like Yki, both Yap and Taz lack a DNA binding domain, and must be associated with 
transcription factors to regulate target gene transcription. Computational prediction, 
based on domain-domain interaction, has identified many transcription factors as 
potential Yap/Taz associating-proteins, some of which are already known to be 
important for cell cycle regulation such as C/EBP and P73. The predicted transcription 
factor TEF/TEAD has been demonstrated to associate with Yap/Taz [58,59,60] and 
initiate ctgf gene expression [61,62]. Ctgf is required for chondrocyte proliferation, 
angiogenesis, extracellular matrix production and turnover. Moreover, Yap and Taz 
have distinct partners that regulate expression of different sets of target genes. For 
instance, Taz interacts with TBX5 [63] and Smad2/3/4 [64], while Yap interacts with 
ErbB4 [65] and Smad7 [66]. Both Yap and Taz can be phosphorylated and inhibited by 
Lats. They are the only two identified effectors of the mammalian Hippo signaling 
pathway. 
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1.3    Liver function and liver development 
The liver is the largest solid organ of the body and has essential functions in 
metabolism, detoxification, and biosynthesis. It is located in the upper right-hand 
portion of the abdominal cavity, beneath the diaphragm and on top of the stomach and 
intestines. Nutrients (carbohydrate, fat and protein) from the intestine are further 
digested in the liver and the products are converted into other energy forms (protein, 
glucose, vitamins, etc.), which can be either stored or released into blood to meet body 
consumption. It also filters body wastes (bilirubin, ammonia) and toxins (alcohol, drugs 
and chemicals) from blood and transforms them into either water-soluble or bile-
soluble materials for elimination through kidney or as feces, respectively. Therefore, 
liver functions as a guardian to keep the body healthy.   
        The major cell type of the liver is the hepatocyte, which constitute about 70% of 
the whole liver mass and are the main cell type that performs liver function [67]. The 
remaining 30% of cells are non-parenchymal cells, including BECs (Biliary Epithelial 
Cells, also called cholangiocytes), stellate cells, küpffer cells, and sinusoidal 
endothelial cells. Hepatocytes and BECs are epithelial cells that are derived from 
embryonic endoderm, while the other cells are from embryonic mesoderm. The 
development of the liver is a consequence of reciprocal tissue interactions between 
endoderm and nearby mesoderm. It originates from the ventral foregut endoderm 
around embryonic day 8.0 (E8.0) of gestation [68,69]. Hepatic diverticulum forms 
around E9.0 when it is adjacent to the developing heart. At E9.5, the hepatoblasts 
(progenitor cells of both hepatocytes and BECs) delaminate from the anterior portion 
of the hepatic diverticulum and invade the adjacent mesenchyme to form the liver bud 
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[70,71,72]. The reciprocal interactions between endoderm and mesoderm promote 
hepatoblast proliferation and stellate cell formation from the adjacent mesenchyme 
[73,74,75,76]. Between E10.5 to E15, the liver bud grows tremendously due to 
hepatoblast proliferation and latter on differentiation. Biliary epithelial cells emerge 
early on E11.5 [77] adjacent to the portal vein, and keep on differentiating and growing 
while interacting with adjacent endothelial cells and mesenchymal cells. Majority of the 
hepatoblasts differentiate into hepatocytes. The process continues untill the 
characteristic architecture of the liver comes into being, which is around birth.  
        Several signaling pathways are known to be important for BEC development and 
bile duct formation, such as TGFβ signaling, Wnt signaling, and Notch signaling 
(Diagram 3). TGFβ signaling forms a gradient with a higher level in the portal region 
and a lower level in the parenchymal region [78,79]. This gradient is important for 
biliary differentiation as evidenced by suppression of biliary differentiation following 
TGFβ pathway blockage, and ectopic biliary differentiation following TGFβ pathway 
activation. Wnt signaling is temporally activated during biliary differentiation, peaking 
around E12.5 but completely being suppressed after E16.5 [80]. Notch signaling 
(Diagram 4) promotes biliary differentiation and is activated specifically in the portal 
region by its ligand jagged1, which is secreted from portal endothelial cells [81,82,83]. 
This also explains why the bile ducts only forms close to the portal vein. This 
interaction between the portal hepatoblasts and the endothelial cells is essential for 
bile duct development. In human, Jagged1 mutation is responsible for an autosomal 
dominant disorder called Alagille syndrome (AGS) [84,85,86]. Jagged1 and Notch2 
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deleted mouse mimics the human AGS symptom, and therefore being used as a 
model for the study of bile duct development [81,82,87,88,89,90,91]. 
  
 
 
Diagram 3. Molecular signals regulating the bile duct development. The development 
of the bile duct can be roughly divided into two steps: the BEC fate determination, and 
the tubular morphogenesis. Some known factors that contribute to the fate 
determination step are the Notch signaling, TGFβ and Tbx3. While Notch and TGFβ 
promote BEC differentiation from hepatoblast, Tbx3 inhibits the process. Notch and 
TGFβ also play a role during the tubular morphogenesis. Notch activates several 
targets genes that are important for the tubular morphogenesis, such as HNF1β, Hes1 
and Sox9, making it to be a major signaling that regulates the bile duct tubular 
morphogenesis. 
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Diagram 4  Notch signaling. Notch signaling is activated via the binding of Notch trans-
membrane receptor with ligand Jagged1 or DLL (Delta-like ligand) from adjacent cells. 
The Notch intracellular domain (ICD) is then cleaved by γ-secretase and translocates 
into the nucleus, where it binds to Recombination signal-binding protein (RBP) and 
initiates Hes and Hey genes expression. 
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        The characteristic architecture of the adult liver is the liver plate. In human and 
swine, the liver plate is lined up by connective tissues and segregated into a hexagon. 
However, murine liver plate is not clearly segregated by connective tissues, although it 
consists of similar anatomic structures: portal triads and a central vein (CV) (Figure. 1 
and Diagram 5). A portal triad consists of a portal vein (PV), a bile duct and a hepatic 
artery. The hepatocytes line up as cords connecting the central vein with portal triads. 
Between the cords are sinusoids that are lined up with endothelial cells. The major 
liver immune cells, Küpffer cells, reside in the sinusoids. Between the hepatocytes and 
the endothelial cells is the space of Disse where the hepatic stellate cells reside. 
Following liver injury, stellate cells can be activated and secrete collagens that 
contribute to liver fibrosis and cirrhosis [92]. Liver architecture is important for proper 
liver function and liver homeostasis. Nutrients and biochemical materials from the 
small intestine enter into liver through the portal vein, and then together with blood 
from hepatic arteries pass through the sinusoids and empty into the central veins. On 
the other hand the bile acids secreted by hepatocytes are collected in hepatic 
canaliculus and flow towards bile ducts. The two flows ensure efficient nutrition 
transportation and biological material recycling between liver and intestine. Under 
some disease conditions, when liver architecture is disrupted by infiltrating immune 
cells or activated liver stem/progenitor cells, the blood and bile acid flows will be 
perturbed and the resulting hepatic injury may elevate the disease status to tumor 
development. 
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Figure 1. Normal adult mouse liver plate and portal triad structure. (A) HE staining 
shows typical mouse liver plate structure: central vein (CV) and portal vein (PV) 
surrounded by hepatocytes. (B) is a higher magnified view of the portal triad as 
squared in (A). Green arrow points to a bile duct and yellow arrow points to a hepatic 
artery.  
 
 
 
Diagram 5   Cell types and functional structures of the liver. 
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1.4   Liver cancer 
 Liver cancer is the third leading cause of cancer-related patient death. The 5-year 
survival rate of patients with liver cancer is less than 10%. Additionally, over 50% of 
liver cancer patients have cancer recurrence within 3 years after tumor removal 
surgery [93,94]. This high mortality is due to both the lack of early diagnosis and the 
quick malignant aggressive nature of liver cancer [95]. Adult primary liver cancer is 
highly associated with HBV and HCV infection which induces chronic inflammation, 
parenchyma regeneration and subsequent liver cirrhosis, dysplastic lesions and 
eventually liver carcinomas [96]. Heavy alcohol abuse and corrupted food intake can 
exacerbate disease severity [97]. Liver stem cell and progenitor cell activation due to 
viral infection, chronic inflammation and cirrhosis can potentially lead to malignant 
transformation.  
 Based on the cellular origin, there are two types of primary liver cancers: the 
hepatocellular carcinoma (HCC) and the cholangiocarcinoma. HCC features 
uncontrolled hepatocyte proliferation and cytoplasmic content decrease. The 
cholangiocarcinoma is characterized by the expanding of poorly organized bile ducts 
due to bile epithelial cell proliferation. The two types of carcinoma cells sometimes co-
exist within one liver tumor, which is believed to be originated from common liver stem 
or progenitor cells which possess dual differentiation abilities into both hepatocytes 
and cholangiocytes (bile ductal cells, biliary epithelail cells) [98]. Tumors with cancer 
stem cells are malignant and frequently relapse after treatment [98,99,100,101]. 
Understanding the roles of cancer stem cells during tumorigenesis may help improve 
liver cancer treatment. Liver stem cells are believed to reside in the bile ducts or the 
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periportal area. However, there has been no specific biomarker to identify them. The 
identification of liver stem cells relies on their morphology of an oval shape (so called 
oval cells) which can be determined by electron microscopy [102].  By using this 
technique, several intermediate progenitor cell types between oval cells and mature 
hepatocytes are identified and classified as Type I, II and III hepatic progenitor cells. 
The rare oval cells are termed as Type 0 cells [102]. In liver disease models, such as 
allyl alcohol-induced hepatic necrosis in rat, the activated periportal cell expansion 
always consists of mixed cell populations of the abovementioned cell types. Since 
more differentiated cell types (like Type II and Type III) appear at later stage and more 
undifferentiated progenitor cells (like Type 0 and Type I) appear at early stage, a 
scheme of dynamic cell differentiation from Type 0 to Type III and finally hepatocytes 
can be illustrated [102]. The available antibodies such as OV-6, A6, OC2-1D11 and 
MIC1-1c3 [103] can only recognize a mixture of these cell types but not a designated 
one.  
1.5   Organ size control 
        Organ size can be determined by the cell number as well as the cell size [104]. 
For example, an elephant heart is bigger than a mouse heart is because it has more 
cells [105], whereas a small wing of some Drosophila strain is a result of smaller cell 
size [106]. A certain organ’s size, however, is determined at a level of the total organ 
mass, which is achieved by coordinately regulated cell number and cell size. A good 
example is that although a tetraploid salamander has twice the cell size of that in a 
diploid salamander, the corresponding organs’ sizes are similar in the two animals 
because the tetraploid salamander has half cell number of the diploid salamander’s 
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[107]. Also, changes in cell number from deregulated cell proliferation do not 
necessarily result in changes in organ size [108,109]. These experimental findings 
suggest that there is a “total mass setting point” mechanism, which functions to link the 
regulation of cell number (proliferation) and cell size (growth).  
         In the studies of the “total mass setting point” mechanism, genetic screening has 
been carried out in Drosophila looking for genes whose mutations can decouple the 
cell number - cell size regulation and result in dramatic organ size changes. The 
insulin-signaling pathway was identified to be an important organ size control pathway 
in that it regulates cell growth without affecting cell proliferation (reviewed in [110]). 
Mutations of its components often affect cell growth and consequently change cell size 
only and result in changes in organ size. It functions through PI3K/AKT pathway and 
regulates mRNA transcription as well as protein translation. The consequence is the 
change in RNA:DNA ratio and protein amount, which contributes to the change of cell 
size [111]. The size control mechanism by the insulin pathway has been further 
confirmed in mammalian system: in mouse heart, increase or decrease the activity of 
this pathway results in a corresponding heart size change, and this change is 
associated with comparable increase or decrease in myocardiocyte size [112]; in 
mouse liver, transient activation of the insulin pathway by activation of Akt triggers a 3-
4-fold liver size increase within days due to hepatocyte hypertrophy without significant 
hepatocyte proliferation [113]. The importance of insulin pathway in determining the 
“total mass setting point” is further supported by data from liver regeneration 
experiments, in which it compensates hepatocyte proliferation deficiency through 
promoting cell growth [114,115]. The most striking phenomenon is that disrupting PI3-
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K/PDK1/Akt pathway, the main cytoplasmic kinase complex of the insulin pathway, 
does not affect hepatocyte post-PH mitotic response, rather, significantly ceases liver 
regeneration due to the inability of cell growth [115]. These findings supports that the 
insulin-signaling pathway is a conserved organ size control pathway, and it plays 
important roles in the “total mass setting point” mechanism through regulating cell 
growth/size.   
        The recent identified Hippo pathway has been also connected to organ size 
control mechanism. However, instead of regulating cell growth, the Hippo pathway 
appears to be important for cell number regulation by balancing cell proliferation and 
apoptosis. Deregulation of the Hippo pathway in Drosophila results in overgrowth of 
the imaginal discs and enlargement of the corresponding adult organs without 
affecting cell size and tissue patterning (reviewed in [116]). Several identified Hippo 
pathway target genes are related with cell cycle progression (bantam, cyclin E) and 
cell survival (diap1), suggesting a role of the hippo pathway in cell number regulation. 
However, whether the Hippo pathway is a conserved organ size control pathway in 
different species and contributes to the “total mass setting point” mechanism needs 
further investigation. 
        Studying the mechanisms in organ size control is important not only because the 
organ size control is a fundamental biological question, but also because the potential 
genetic linkage between this mechanism and tumorigenesis. Genes contributing to the 
insulin pathway, the known organ size control pathway, are often mutated in 
tumorigenesis. PTEN affects organ size through negatively regulates cell size 
[117,118,119]. It negatively regulates the insulin signaling and is one of the most 
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frequently mutated genes in many types of human tumors [120]. Tuberous sclerosis 
complex 
(TSC), another component of the insulin pathway, is a tumor suppressor [121], whose 
mutation results in Drosophila eye enlargement due to the dramatic increase in cell 
size [122]. Exploring the organ size control mechanism may help to better understand 
tumorigenesis.  
1.6   Liver regeneration 
        The liver is a unique organ that maintains its regenerative ability throughout its 
lifetime [123]. Liver regeneration can be triggered by hepatocyte injury (toxin intake) or 
hepatic tissue loss (hepatectomy) [124]. While toxins often induce liver inflammatory 
responses and progenitor cell expansion in addition to hepatocyte proliferation, 
surgical resection only induces hepatocyte proliferation. Therefore using surgical 
resection to induce liver regeneration is widely used in studies of liver regeneration. In 
addition, the reproducibility of partial hepatectomy (PH) in terms of liver mass removal 
and the precision of ensuing event timing have made PH a preferred approach for 
experimental liver regeneration study [125,126].  
        Full liver re-growth by surgical induced liver regeneration takes about 7-10 days 
in rodents. The whole process is characterized by a synchronous induction of normally 
quiescent hepatocytes to reenter the cell cycle, which leads to a complete restoration 
of liver mass [127]. The major cellular events can be briefly divided into three phases: 
the priming phase (0h-12h after PH), the proliferation phase (12h-72h after PH), and 
the growth termination phase (72h-7 days after PH) [128]. Right after PH (priming 
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phase), the non-paranchymal cells (mainly the Küpffer cells and stellate cells) are 
activated and secrete cytokines (e.g. IL-6) and growth factors (e.g. HGF) to induce 
hepatocyte proliferation (proliferative phase). The initiation of hepatocytes cell cycle 
reentry is a complicated process and requires the activity of multiple pathways, which 
also link to each other in some way and function in a redundant manner. One well-
known signaling that activates hepatocyte proliferation is the IL-6 -Jak-Stat pathway. 
IL-6 accounts for about 40% of the immediate early genes in the priming stage 
[129,130] and IL-6 KO mice show striking deficit in DNA replication after PH [131]. IL-6 
signaling can activate cell cycle regulators, such as Cycin D1, a hall maker for 
hepatocyte cell cycle reentry. Increased expression of Cyclin D1 activates Cdk4/6, 
which promotes hepatocyte G0-G1 transition. The importance of Cyclin D1 in 
hepatocyte cell cycle reentry is affected by: transient expression of cyclin D1 is 
sufficient to initiate hepatocyte proliferation [132,133]; diminished expression of Cyclin 
D1 is related with impaired liver regeneration [131,134]. Another important factor that 
regulates hepatocytes cell cycle re-entry is P21, which is a universal Cyclin kinase 
inhibitor and promotes cell cycle exit [135]. Liver regeneration impairment resulting 
from blockage of the G1/S transition can be restored by P21 deletion [136], suggesting 
P21 plays an pivotal role in suppressing G1/S transition. P21 expression peaks around 
24 hours after PH, when hepatocytes begin to exit the cell cycle. The termination 
phase mainly involve extracellular matrix synthesis and reestablishment, hepatocyte 
and bile duct rearrangement [128]. Complete liver function recovery is around 14 days 
after PH. 
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         Our lab investigated the Hippo pathway function in vivo by generating conditional 
knockout mice for each main component and analyzing the phenotypes of these 
mutant mice. We found that the Hippo pathway is important for liver homeostasis and 
tumor suppression. In addition, it may contribute to liver development through 
controlling the BEC differentiation. Finally, it is not a critical pathway for the “total mass 
checkpoint”-organ size control mechanism; however, it does play an important role in 
regulating hepatocyte cell-cycle reentry during the liver regeneration. Our study is 
among the first ones to address these questions, and the results may help understand 
the molecular mechanisms of fetal liver development and adult liver homeostasis.  
 
 
 25 
 
 
 
 
 
 
 
 
 
CHAPTER 2: RESEARCH RATIONALE 
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         We hypothesized that the Hippo pathway is a tumor suppressor pathway as well 
as an organ size control pathway in the mammalian system according to its function in 
Drosophila and the conservation of the components in mammals. In Drosophila, 
deregulation of the Hippo pathway kinase cassette and up-regulation of its nuclear 
effecter Yki causes cell uncontrollable proliferation and organ tumor-like growth. In 
addition, dysregulation of the Hippo pathway in Drosophila decouples the cell 
proliferation and cell growth in imaginal discs and leads to adult organ size 
enlargement. The two topics are related in that organ size control is one of the 
mechanisms for maintaining tissue homeostasis.  
2.1  Role of Hippo pathway in mouse liver tumorigenesis.   
        Genes that affect cell proliferation or growth can be oncogenes (e.g. myc 
[137,138]) or tumor suppressors (e.g. p53 [139,140], pten [120]). In human, 
dysregulation of the Hippo pathway main components in tumor tissues has been 
reported. Yap and Taz are abnormally expressed in a variety of human cancers, 
including colonic adenocarcinoma, lung adenocarcinoma , ovarian serous 
cystadenocarcinoma, HCC, and breast cancer [50,141,142]. Decreased expression of 
Mst1 and Mst2 due to promoter hypermethylation has been reported in soft tissue 
sarcomas, which suggests their potential roles as tumor suppressors [40]. Mst can be 
activated by forming a heterodimer with members from the tumor suppressor family of 
Rassf [55] whose expression is often inactivated by epigenetic silencing in human 
cancers. Given that the Rassf family has at least six members and they do not exist in 
Drosophila, we can assume that the mammalian Hippo signaling pathway could have 
 27 
distinct and complicated regulatory mechanisms. Sav1 deletion in human cancer is 
rare and has only been reported in one colon cancer and two renal cancer cell lines 
among 52 cancer cell lines [42]. Lats1 and Lats2 are believed to be broad governors of 
cellular homeostasis. Their deregulations have been reported in astrocytoma [43], 
breast cancer [44], leukemia [143], soft tissue sarcoma [144], lung cancer [145] and 
prostate cancer [146]. Taz is required for kidney and lung organogenesis [147] and 
breast cancer stem cell quiescence [141,148]. We therefore hypothesized that the 
Hippo pathway is a tumor suppressor pathway in mammals, and we used several 
genetically engineered mouse models to test this hypothesis. Uncontrolled cell 
proliferation and tissue overgrowth are features of tumorigenesis.  
        The mammalian Hippo pathway is complicated by the paralogs of the main 
components as they potentiate more regulatory interaction with other factors. Null 
mutations of the major components of the Hippo pathway have been generated, and 
results revealed significant functional redundancy between the paralogs. Mst1 or Mst2 
deficient mice are relatively normal. But Mst1 and Mst2 double deficient embryos die 
around E8.5 due to hematopoietic defects [149], suggesting a strong functional 
redundancy between Mst1 and Mst2. Sav1 is also required for embryonic development 
because its germline deletion causes embryonic lethality at around E17.5 to E18.5 due 
to defects in placenta vascularization [150]. Lats1 null mice are viable but lack 
mammary glands. They are infertile, exhibit growth retardation, and develop soft tissue 
sarcoma and ovarian tumors [151]. Lats2 null mice show a more severe phenotype as 
they die before E12.5 and also exhibit growth retardation [152]. Both observations 
suggest that Lats1 and Lats2 have distinct functions and are both required for 
 28 
embryonic development. The earlier embryonic lethality of Lats1/2 double deleted 
mutants (unpublished data) implies that functional redundancy exists between Lats1 
and Lats2. Yap-null mice die around E8.5 with defects in yolk sac vasculogenesis, 
chorioallantonic fusion, and body axis elongation [153]. Viable Taz null mice have 
defects in the kidney [147,154]. On the other hand, potential functional redundancy 
and a possible synergistic relationship between Yap and Taz are reflected by the 
observation that Yap/Taz double null embryos die before the 16-cell morula stage 
[155]. Embryonic lethality hinders further analysis for the potential tumor suppressor 
function of this pathway in adults, and therefore gene conditional deletion in adult 
tissues is required. The dissection of how the Hippo pathway contributes to tissue 
homeostasis and tumorigenesis in the adult is important for uncovering its role during 
human tumorigenesis and providing valuable information for cancer treatment. 
        The Cre/Loxp recombination system is the most commonly used conditional gene 
deletion strategy. By crossing the mice bearing loxp-flanked allele(s) in the functional 
domains of the target genes with the mice bearing either tissue specific promoter-
driven cre or tetracycline-inducible cre, we generated series of tissue-specific/inducible 
conditional gene knockout mice. Defects were seen in mammary glands terminal end 
bud (TEB) cell differentiation (Figure 2A), intestinal villus development (Figure 2B), 
brain, liver, ovary, and testis epididymis (data not shown). Although the Hippo pathway 
is involved in the development of almost all examined tissues, the liver seems to be 
the most susceptible organ to the Hippo pathway deficit. Low-frequency gene deletion 
of Mst or Sav1 in the liver (as evidenced by low and scattered cre expression driven by 
non-liver specific MMTV [156] and CAGGS [157] promoters) led to liver tumorigenesis. 
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Our finding is consistent with the previous report about Yap overexpression resulting in 
liver cancer [34]. The dramatic phenotypes from altered expression of Hippo pathway 
components make liver an ideal organ model for studying the in vivo function of this 
pathway. In addition, this study also has clinical significance. In a study consisting of 
177 patient liver tumor biopsies, 62% of them show Yap over-expression and nuclear 
accumulation, which significantly correlate with poor differentiated tumor cells. Yap 
nuclear accumulation correlates with tumor relapse after tumor resection and low 5-
year patient survival rate [51], which makes Yap become a new prognostic marker for 
HCC. Therefore, figuring out how the Hippo pathway regulates Yap activity and 
contributes to the tumorigenic process may help to develop therapeutic approaches for 
liver cancer. 
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Figure 2. Sav1 deletion in mammary gland and Mst1/2 deletion in intestine. (A) On 
18th day of mice pregnancy, wild type TEB cells differentiate into milk-secreting 
alveoli, which are large and plump; but the MMTV-cre;Sav1 TEB cells do not 
differentiate well. The mutant alveoli are small and do not contain much milk as 
compared with the wild type. (B) In intestine, the wild type duodenum has well 
developed and organized villi and crypt layers, whereas the villin-cre;mst1/2 
duodenum has thinner basal layer and disorganized crypt layers, together with 
massive cell vacuolation.    
 31 
        To specifically analyze how the Hippo pathway kinase cassette (Mst/Sav1/Lats) 
regulates Yap/Taz function in the liver, we used alb-cre to delete the Hippo pathway 
genes in all (>90% [158]) hepatocytes, as well as in the BECs. The alb-cre mouse line 
has been widely used for liver-specific gene knockout studies. The albumin promoter 
activates around E9.5 [159]; however, 90% gene deletion will not be achieved until 
after birth [158]. In this manner, alb-cre mediated gene deletion occurs in both 
hepatocytes and BECs in a developed liver, and the deletion in the embryonic liver is 
mosaic. Alb-cre mediated gene deletion usually does not cause embryonic lethality, 
except if the interested genes are essential for liver function. An example is C/EBP, an 
important transcription factor for liver energy homeostasis [160].  
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2.2  Role of Hippo pathway in mouse liver regeneration 
        In Drosophila, deregulated Hippo pathway results in overgrown imaginal discs 
and corresponding increase in adult tissue due to enhanced cell proliferation and 
reduced cell apoptosis. Change of cell size is not found, and the overgrown tissues still 
maintain normal patterns. Hippo pathway is thus linked to an organ size control 
mechanism and, unlike the insulin pathway, it may contribute to the “total mass setting 
point” mechanism by regulating cell number without affecting cell size.  
       Similar phenomena have been observed in the mammalian system. Enlarged 
heart [161] and liver [34,37,38,41] sizes due to uncontrolled cell proliferation have 
been observed when the Hippo pathway is deregulated. In mouse liver, the hepatocyte 
number but not size shows a correlation with Yap amount: liver size dramatically 
enlarges when Yap over-expression is induced to promote hepatocyte proliferation; 
whereas the liver shrinks towards its normal size due to hepatocyte apoptosis when 
withdrawing the induction [34]. Pro-proliferation and anti-apoptosis are also observed 
in Mst mutants [41]. However, whether these phenomena are the consequences of the 
disturbed organ size control mechanism or just a disease symptom need to be 
clarified.  
       Previous reports about liver size control suggest that the liver size is well 
regulated by complicated signaling networks and the majority of gene deletions only 
impair rather than totally cease the liver regeneration. For example, myc functions to 
promote cell proliferation and is activated during the priming phase of liver 
regeneration [162]. However, Myc deleted liver still can regenerate and grow back to 
its original size [163,164], implying its function can be compensated by other liver size 
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control mechanism. However, whether and how much the Hippo pathway accounts for 
liver size control needs to be further investigated.  
        Liver size setting point is recognized to be 4~5% of the host’s body weight, and it 
is strictly regulated throughout lifetime by liver’s unique regeneration ability. 
Theoretically the liver regeneration is regulated by the size control mechanism, and 
any deficit in liver regeneration should reflect disturbances of the size control 
mechanism. We used partial hepatectomy (PH) technique to induce liver regeneration 
to test our hypothesis. The benefits of using PH to induce liver regeneration are: first, 
the PH technique has been well established [165] and extensively studied 
[128,166,167,168], which technically ensures the project’s performance. Second, PH 
induced liver regeneration is a process of synchronized hepatocyte proliferation with 
well defined timing of cell cycle events, which eases the analysis by providing plenty of 
samples for any regeneration phases. Third, PH induced liver regeneration is a normal 
biological phenomenon happened in an mature organ, therefore excluding the 
signaling interferences from developmental process or disease effect.   
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CHAPTER 3:  MATERIAL AND METHODS 
 35 
 
3.1 Breeding and generation of mice with sav1 deletion, mst1;mst2 double deletion, 
lats1;lats2 double deletion, and Yap;Taz double deletion 
      Sav1 fl/fl, mst1 fl/fl, mst2 fl/fl, lats1fl/fl, and lats2fl/fl mice were designed and generated 
by Randy Johnson (PhD, MD Anderson Cancer Center). These mice have a mixed 
genetic background of C57BL/6, 129SvEvTac and CD1. Yapfl/fl and tazfl/fl mice were 
design and generated (but not published) by Eric Olsen’s lab (PhD, UT Southwestern 
Medical Center, Dallas, TX). Yapfl/fl;tazfl/fl mice were bred with our mouse colony, and 
therefore they also have a mixed genetic background. Sav1fl/fl, mst1 fl/fl, mst2 fl/fl mice 
were subsequently bred to alb-cre, MMTV-cre, villin-cre and CAGGS-creER(T2) mice 
followed by backcrossing to homozygous floxed animals. Lats1fl/fl, lats2fl/fl, yapfl/fl;tazfl/fl 
were bred to alb-cre mice followed by backcrossing to homozygous floxed animals.  
        All mice were housed in a conventional facility with a 12-h light/dark schedule and 
access to food and water ad libitum. All procedures were approved by the University of 
Texas, M. D. Anderson Cancer Center Animal Care and Use Committee. 
 
* “fl/fl” will be omitted in the following paragraph. For example, “alb-cre;mst1/2” 
represents “alb-cre; mst1 fl/fl; mst2 fl/fl ”. 
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3.2   Genotyping 
        Genotype of each mouse was analyzed by PCR. Chromosome DNA was 
extracted from tail lysate from 2~3 weeks old mice using previously described 
techniques [169,170,171]. Primers (Table 2.) were designed to detect the floxed exon 
in each gene. The PCR conditions were 35 cycles of 95°C for 30 seconds, different 
annealing temperatures (Table 2.) for 30 seconds and 72°C for 1 minute. PCR 
products were run in agarose gel added with ethidium bromide. Genotypes were 
determined according to specific bands (Table 3.) 
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Table 2. Primer information 
Gene Primer sequcence (5’ – 3’) A.T. (°C) 
F CCTGCTTCAGTGTTGGCTCTTGATTTTCCT 
mst1 
R TAGACCAGCCAGGGCTAGAGTGAAACCTTG 
50 
F GTTCAGGGTCCCACCAAGAGTCGCTTCATT 
mst2 
R TGTCTAGCTGCTGATGACACTGAACTTCTGGC 
55 
F TGTCAGTGTAAAATGGCCACA 
sav1 
R TTGGGAATGGTTTTACAAGTTT 
50 
F TTGTTGCTGGTGTTGTTTCC 
lats1 
R ATGAATGAACCTGAGGCTGC 
55 
F ATCCTAGCACTCAGGAGGCA 
lats2 
R ACACATTCCCCTCCACTGAC 
55 
F ACATGTAGGTCTGCATGCCAGAGGAGG 
yap 
R TGGTTGAGACAGCGTGCACTATGGAGC 
60 
taz F GGCTTGTGACAAAGAACCTGGGGCTATCTGAG 62.5 
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R AACTGCTAACGTCTCCTGCCCCTGACCTCTC 
F TCCAATTTACTGACCGTACACCAA 
cre 
R CCTGATCCTGGAATTTCGGCTA 
55 
 
F: forward primer 
R: reverse primer  
A.T. :  Annealing Temperature 
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Table 3. PCR product size 
Gene Allele  PCR product size (bp) 
Wild type 319 
mst1 
loxP 400 
Wild type 213 
mst2 
loxP 370 
Wild type  250 
sav1 
loxP 405 
Wild type 182 
lats1 
loxP 350 
Wild type 235 
lats2 
loxP 380 
Wild type 457 
yap 
loxP 600 
taz Wild type 496 
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loxP 655 
cre cre 450 
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3.3  Tissue processing and paraffin slides preparation 
       Mice were sacrificed by cervical dislocation. Liver tissues were cut into 5 mm-thick 
pieces and fixed with 4% PFA overnight at 4°C. The next day, the fixative was washed 
off with PBS, and then the tissues went through increasing alcohol gradient  (70%-
90%-100%). After dehydration, tissues were cleared in Xylene for 45 minutes and then 
put into 65°C liquid paraffin for over 6 hours with three times paraffin change. Lastly, 
the tissues were put into metal cassette and embedded in paraffin by cooling down to 
4°C. Paraffin blocks were cut into 5 µm sections and slides were put on 37°C heater 
overnight to ensure tissue attachment. 
3.4  Immunostaining with paraffin slides 
       Slides were pre-heated in 65°C oven for 1 hour to melt the paraffin and also 
enhance tissue attachment. They were then deparaffinized in 3 changes of Xylene 
with 15 minutes in total, followed by rehydration in decreasing alcohol gradient until 
into water (100% - 90% - 70% - ddH2O). Heat antigen retrieval was carried out in 
sodium citrate buffer (10mM Sodium Citrate, 0.05% Tween 20, PH6.0) for 15 minutes 
using a steamer. After cooling down for 20 minutes, the antigen retrieval buffer was 
washed off with PBS for 5 minutes and three times. Endogenous biotin was blocked by 
putting the slides into 3% H2O2 (in Methonal) for 15 minutes, followed by antibody 
blocking with 5% normal horse (or goat) serum for 1 hour at room temperature. After 
that, slides were added with primary antibody (Table 2) and incubated in a wet 
chamber at 4°C overnight. The next day, after washing off the primary antibody with 
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PBST, 5 minutes for 3 times, tissues were incubated with HRP or fluorescence 
conjugated secondary antibody for 1 hour at RT. The positive staining signal was 
developed with DAB reagents (Vector Laboratory, SK-4105). The tissues were 
counter-stained with Mayer’s hematoxylin (Fisher Scientific, TA060MH), and then 
dehydrated in increasing alcohol gradient into Xylene. Slides were then sealed with 
Permount (Fisher Scientific, S70104) and signals were detected with microscope 
under bright field.  
 
* note: For fluorescent staining, seal the slides with anti-fade mounting solution 
with DAPI (invitrogen, CEL36935), and the slides are ready to view under 
microscope. 
 
3.5  Frozen section and immunostaining (only for oval cell markers) 
       Liver samples were cut into 5 µm-thick pieces and immediately immersed into 
CRYO-OCT Compound (Fisher Scientific, 14-373-65). After adjusting the tissue 
position, the OCT cassettes were carefully held and put on top of isopentane, which 
had been pre-chilled by putting into liquid nitrogen for at least 10 minutes. After about 
2 minutes, when the OCT was frozen into a block, the block was either stored in -80°C 
or directly sectioned. For the staining of the oval cell markers (Table 2), slides were 
briefly fixed in cold acetone (-20°C) for 5 minutes. After washing off acetone with PBS 
for three times and each time for 2 minutes, slides were added with 5% goat serum 
and incubated for 10 minutes at room temperature to block non-specific antibody 
affinity. Slides were then incubated with primary antibody for 30 min. After the primary 
 43 
antibody was washed off with PBS for 2 minutes in a total of three times, Cy3-
conjugated secondary antibody was added and the slides were incubated at room 
temperature for 15 minutes. Again with PBS wash to get rid of excessive secondary 
antibody, slides were sealed with anti-fade mounting solution with DAPI (invitrogen, 
CEL36935), and signals were detected with confocal microscopy.  
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Table 4. Antibody information 
Antibody Source 
Catalog 
number 
Applied 
experiment 
Dilution 
ratio 
A6 
Dr. Valentina Factor 
(NIH) 
 IF 1:500 
BrdU Abcam ab6326 IHC 1:100 
CK19 
Dr. Milton Finegold 
(Texas Children’s 
Hospital) 
 IF, IHC 1:1000 
Cyclin D1 Cell signaling 2922 WB 1:1000 
F4/80 
BD 
Biosciences 
552958 IF 1:200 
HNF4α Santa Cruz sc-101059 IF 1:200 
Lats1 Cell signaling 9153 WB 1:1000 
MIC1-1c3 
Dr. Craig Dorrell 
(Oregon Health 
Sciences Center) 
 IF 1:20 
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Mst1 Cell signaling 3682 WB 1:1000 
Mst2 Cell signaling 3952 WB 1:1000 
OC2-1D11 
Dr. Craig Dorrell 
(Oregon Health 
Sciences Center) 
 IF 1:20 
PCNA Cell signaling 2586 WB 1:1000 
Phospho-Lats1 Cell signaling 9159 WB 1:1000 
Phospho-
STAT3 
Cell signaling 4113 WB 1:1000 
Phospho-
Yap/Taz 
Cell signaling 4911 WB 1:1000 
P21 Cell signaling 2946 WB 1:1000 
Sox9 Millipore AB5535 IF 1:500 
STAT-3 Cell signaling 9139 WB 1:1000 
Yap Cell signaling 4912 WB, IHC 1:1000, 1:500 
Taz BD Pharmingen 560235 WB 1:1000 
 
WB: Western Blot 
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IHC: Immunohistochemistry 
IF: Immunofluorescence 
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3.6  PAS staining 
       Paraffin tissue sections were deparaffinized and rehydrated to water, followed by 
being oxidized in 0.5% periodic acid solution for 5 minutes. After being rinsed with 
distilled water for three times, slides were put into Schiff’s reagent (Sigma-Aldrich, 
3952016) and incubated at room temperature for 15 minutes. The color (pink) was 
developed under running warm tap water for at least 5 minutes. The slides were then 
counterstained with Mayer’s hematoxylin for about 1 minute. After wash and 
dehydration, the tissues were then sealed with Permount and ready to view under the 
microscope. 
 
3.7   Quantitative PCR 
        For each mouse, about one gram liver tissue was cut and put into 1 ml TRIZOL 
reagent (Invitrogen, 15596-025), followed by being broken down using an electronic 
homogenizer. Five hundred-microliter chloroform was then added to each sample tube 
and mixed with TRIZOL well by vortex. The samples were then centrifuged at the 
highest speed (14000g), and the supernatant was then transferred into Qiagen 
RNeasy mini column for binding. After centrifuge, the mRNAs binding to the column 
were washed by the RW buffer (Qiagen RNeasy Mini Kit, 74104), followed by washing 
with 70% ethanol (prepared in DEPC-treated water). Finally, mRNAs were eluted with 
into 15 ul RNase-free water. mRNA concentration and purity were checked with 
NanoDrop 1000. Quantitative RT-PCR analysis was carried out using One-Step 
TaqMan gene expression assays (Applied Biosystems) according to the 
manufacturer’s instructions.  
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Gene Assay ID 
lats1 Mm01191883 
lats2 Mm01321139 
yap Mm00494237 
taz   Mm00513560 
gapdh Mm99999915 
 
 
3.8  Microarray analysis 
       Illumina Total Prep RNA Amplification Kit (Ambion) was used for preparation of 
biotin-labeled cRNA samples. The microarray analysis was previously described [38]. 
Five hundred nanograms of total RNA was used for the cDNA synthesis, amplification 
and biotin labeling. 1.5 µg of biotinylated cRNAs was hybridized to the Illumina mouse-
6 BeadChip v.2 microarray. Signaling reading is performed by the Microarray Core 
Laboratory of UT Health Science Center in Houston. Heat-map of expression was 
generated by Treeview. Gene ontology assay was performed using the DAVID web 
tool.  
 
3.9    Protein extraction  
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         Fresh harvested liver tissues were broken down into cells using a glass-teflon 
homogenizer, or underwent perfusion to enrich hepatocytes. Then, cells were forced to 
pass through a strainer to get rid of the connective tissue, and the hepatocytes were 
collected into a 50 ml conical tube. The cells then underwent two times wash with PBS 
and re-suspended in RIPA buffer (Cell signaling, #9806) added with protease inhibitor 
(Roche, 04693132001) and phosphatase inhibitor (Roche, 04906837001). The cell 
suspension was then put on ice for at least 30 minutes for sufficient lysate. Cell debris 
was separated from lysate by centrifuging the tube at the maximum speed (14,000 
rpm) for 5 minutes. The supernatant was transferred to a new clean tube, and about 2 
ul aliquot was used for protein concentration measurement;  
* Cytoplasmic and nuclear portion of proteins were extracted by NE-PER Nuclear and 
Cytoplasmic Extraction Reagents (Thermal Scientific, #78835) by following 
manufacture’s protocol. Protein concentrations were measured by using BCA Protein 
Assay Reagents (Thermal Scientific, 23227) according to the manufacture’s protocol. 
 
3.10    Western blot: 
         Protein samples were denatured via boiling for 5 minutes with protein loading 
buffer containing 5% beta-metheltransferase. Denatured samples were run on 10% 
acrylamide denatured gels for 2 hours at 80 volts, followed by semi-dry transfer to 
PVDF membranes (Millipore, IPFL10100) for 2 hours. The membrane containing 
proteins was blocked from non-specific antibody binding with 5% milk in TBST for 1 
hour at room temperature, and then incubated with primary antibody (Table 4) in 5% 
BSA at 4℃ overnight. The next day, secondary antibody was added after the primary 
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antibody was washed off, and incubated with membrane at room temperature for 30 
minutes. After further wash, membranes were developed by enhanced 
chemiluminescence (ECL, PerkinElmer, NEL103001EA), and signal was detected by 
X-ray film. 
 
3.11  Hepatocytes enrichment (liver perfusion) 
        Prepare for the experiment by warming up HBSS (Invitrogen # 14170-11, 
0.3mg/ml collagenase D), EBSS (Invitrogen #14155-063, 0.5mM EGTA) and Rinse 
Medium (Invitrogen # 17704-024) to 37°C in water bath. Mice were then anesthetized 
with IP injection of avertin (400-500ul/mouse). Mouse anesthetizing status was 
checked by pinching the mouse toes for pain reflex. The mouse should not respond if 
anesthetized. The mouse was body stretched by pinning the hand and feet to the 
working platform. A U-shape incision was made to expose liver and inferior vena cava. 
Buffer-fly needle was inserted into inferior vena cava. Right after the pump was turned 
on, portal vein was cut to provide for exit of blood and perfusion liquid, and thus to 
establish the perfusion reagents flow from the liver central vain to the portal vain. The 
perfusion with EBSS lasted for 1-2 minutes (about 40 ml with pump set to 6-7, or 7-8 
speed) and then switched to HBSS and perfused for 2-3 more minutes. When the liver 
became soft, the pump was stopped and the liver was cut out. Gallbladder and fat 
were removed by cutting off. Liver was then put in a 10cm petridish containing 20ml 
RM and gently squeezed with two cell scrapers to release the hepatocytes from 
connective tissue. The cells were then passed through a strainer into a 50ml Conical 
tube. After the cells were rinsed with additional 10ml RM, they were spin at 600 rpm 
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for 2 minutes and re-suspend in 10-25 ml RM. To remove the dead cells, Percoll 
solution was prepared by mixing 15ml Percoll (Sigma #P4937) and 10ml DPBS in a 
new 50ml conical tube, and cell suspension was slowly added into the percoll mixture. 
The tube was centrifuged at 600rpm for 10 minutes, and dead cells were sucked off 
from the upper layer. The remaining cell pellet was re-suspended and washed with 
RM, followed by RNA isolation or protein extraction. 
 
3.12   Partial hepatectomy 
         Five to 6 week old alb-cre;mst1/2 mice and 7-8 week old alb-cre;yap/taz mice 
were used for performing 2/3 PH. The wild-type littermates were used as 
corresponding controls. The mice were anesthetized with IP injection of avertin. After 
briefly rinsing the feather with 70% ethonal, an excision was made in the middle of the 
abdomen to expose the whole liver. Cotton tips were used to lift the left lobe and put a 
15 cm silk suture under it. The suture was moved towards vena cava and a tie was 
made close to it. The entire left lobe was removed with scissors. The middle lobe was 
removed in a similar way but attentions were paid to not tie too close to vena cava. 
Blood was briefly cleaned by using cotton tips, and the abdomen was closed up by 
sewing the muscle and then the skin with silk suture. Morphine (5 mg/kg) was injected 
to reduce pain, and then the mice were put on 37℃ incubator for recovery. Mice were 
sacrificed at select time intervals: 0 hour (h), 6h, 24h, 48h, 72h, and 7days (7d) after 
PH and the livers were harvested for protein extractions and paraffin sections. At 14 
days, measurements were acquired for liver/body weight ratio. All the animal 
procedures were performed in accordance with the MD Anderson Cancer Center 
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institutional guidelines using an approved animal protocol by the Institutional Animal 
Care and use committee. 
 
3.13 Statistical Analysis 
         Student T-test was applied in MicroSoft Excel for two-sample comparison. One-
way ANOVA was used in SSPS program for three-sample comparison. Survival data 
was analyzed using Kaplan Meier statistical method, and the survival curve was 
generated in SSPS program. 
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CHAPTER 4:  RESULTS  
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4.1  Mst and Sav1 are required for liver tumor suppression 
       Loxp-floxed alleles for mst1 and mst2, sav1 were successfully generated [38]. The 
mst1/2 fl/fl and sav1 fl/fl mice showed no detectable abnormalities. Alb-cre;mst1 mice 
and alb-cre;mst2 mice were also phenotypically normal up to 1 year of age. They 
eventually developed liver tumors at around 24 months of age, implying they both are 
required for liver homeostasis. However, a severe phenotype was observed when 
combining Mst1 and Mst2 deletion: alb-cre;mst1/2 (double deletion) mice developed 
multiple nodular tumors in the liver within 4 months after birth and died around 6-7 
months (Figure 3C), implicating that significant functional redundancy exists between 
Mst1 and Mst2 in suppressing liver tumorigenesis. The multiple gray-white nodular 
tumors were identified as HCC (Figure 3F). Sav1-deleted livers showed a similar but 
milder phenotype as compared with Mst1/2 double deleted livers. A few scattered 
gray-white nodular tumors developed in the Sav1-deleted liver at about 8 months old. 
The slower progression of liver tumors in Sav1 mutants allowed the mice to survive 
longer and the tumors to fully develop (Figure 3B). Both HCC (Figure 3D) and 
cholangiocarcinoma (Figure 3E) were observed in Sav1 mutants at around 18 months 
of age. These observations revealed that both Mst and Sav1 are liver tumor 
suppressors.  
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Figure 3. Hepatoma formation in Mst and Sav1 mutants. Wild-type livers display a 
normal appearance, devoid of tumor foci (A). In contrast, conditional deletion of sav1 
in hepatocytes results in large, multifocal tumors (B). Likewise, alb-cre;mst1/2 mutant 
livers are significantly enlarged relative to wild type and display multiple focal tumor 
nodules (C). Histological examination (D-E) reveals both well and poorly differentiated 
hepatocellular carcinoma (D and F) and cholangiocarcinoma (E). The data have been 
published [38]. 
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        To find out the cause of tumorigenesis in these mutants, mutants of younger ages 
were collected and analyzed. In contrast to few sporadic hepatocyte divisions in the 
wild type with normal low rate hepatocyte turnover (Figure 4A), the mutant hepatocyte 
showed uncontrolled proliferation (Figure 4B and C) and mutant liver continuously 
enlarged and eventually developed tumors (Figure 4D).  
 
 
Figure 4. Elevated hepatocyte proliferation contributes to both Mst and Sav mutants’ 
liver enlargement. According to BrdU staining, in contrast to wild-type (A), alb-
cre;mst1/2 (B) and alb-cre;sav1 mutants (B) have significantly increased hepatocyte 
proliferation (C). (D) A plot of liver/body as a function of age shows increased liver size 
of mst1/2 mutants at one month. Continued growth is evident at two and three months 
of age. Modest increases in alb-cre;sav1 mutant liver sizes is seen at two and four 
months of age. The data have been published [38].  
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        At 2-month old, there were no visible tumor-like nodules in the Mst mutants, 
although the livers were dramatically enlarged (Figure 5B). Further HE Staining 
revealed that the mutant hepatocytes gradually gained heteromorphism. At 1-month 
old, there was no obvious difference between the wild-type and mutant hepatocytes; at 
2-month old, the mutant hepaotocytes were swollen and their nuclei were smaller and 
pushed to one side of the cells when compared with wild type (Figure 5D). The 
swollen hepatocytes were not filled with excessive glycogen or fatty acids according to 
PAS staining and Oil Red staining, respectively. So far, the cause of mutant 
hepatocyte enlargement is still unknown, as is whether this contributes to liver tumor 
development.  
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Figure 5.  Two-month old Mst1/2 double deleted liver. At this stage, the mutant liver is 
dramatically enlarged but no visible tumor-like nodules are seen (B). Compared with 
the wild type (C), the portal areas of the Mst1/2 double mutants have many leukocytes 
expanding and infiltrating into the liver plates (D). The mutant hepatocytes are swollen 
and their nuclei are more variable and pushed to one side of the cells [38]. 
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4.2  Yap is activated in alb-cre;mst1/2 and alb-cre;sav1 liver tumor tissues 
       Yap is a nuclear effecter of the Hippo pathway and its activation is known to 
promote hepatocyte proliferation and contribute to HCC formation [34]. To see whether 
Yap is activated in Mst and Sav1 mutants, western blots with proteins from enriched 
hepatocytes before tumor formation were carried out. Results showed decreased 
phospho-Lats and phospho-Yap in alb-cre;mst1/2 liver but not in alb-cre;sav1 liver 
(Figure 6A). In both mutant tumor tissues, Yap was nuclear accumulated and the 
protein amount was increased (Figure 6B), which was possibly due to protein 
stabilization after decreased phosphorylation. 
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Figure 6. Yap activation in Sav1 and Mst mutants. (A) Western analysis (by Wouter 
Bossuyt) of alb-cre;sav1 and alb-cre;mst1/2 double mutant tissues show loss of sav1 
protein in alb-cre;sav1 mutants and reduced amounts of mst1 and mst2 proteins in 
alb-cre;mst1/2 mutants. Each lane represents proteins extracted from independent 
mutant livers. Phosphorylations of Yap and Lats are reduced in alb-cre;mst1/2 double 
mutant hepatocytes but not in alb-cre;sav1 mutant cells. Histone H3 (H3) is used as a 
loading control. This datum has been published [38]. Yap staining in tumor tissues 
reveals increased Yap protein amount, as well as Yap nuclear accumulation in tumor 
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cells of both mutants (B).  
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4.3   Lats is required for liver development 
        The loxp-floxed alleles of lats1 and lats2 were generated by Randy Johnson (not 
published). Liver-specific deletions of Lats1 and Lats2 were achieved by combining 
lats1fl/fl lats2 fl/fl homologs with alb-cre. The deletion efficiencies for both genes were 
about 80% as assessed by quantitative PCR (Figure 7).  
 
 
 
Figure 7  Quantitative analysis of Lats1 and lats2 gene deletion efficiency mediated by 
alb-cre. 
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        Lats1/2 double mutants died from severe hypoglycemia on the first day of birth 
(P0). According to PAS staining (Figure 8), two factors contributed to severe 
hypoglycemia: hepatocyte loss due to hepatic necrosis and decreased glycogen 
synthesis ability of hepatocytes. G/O assay with microarray data revealed essential 
liver metabolic functional defects, including catalysis and biosynthesis (Figure 9C). 
Furthermore, many up-regulated genes after Lats deletion were also up regulated in 
Yap over-expressing liver (Figure 9B).  
 
 
Figure 8. PAS staining on P0 Lats mutant livers. The result shows decreased glycogen 
synthesis in Lats1/2 mutant hepatocytes as compared with that in the wild type. The 
PAS staining is negative in the necrotic area (circled by the red dot line) and ductal 
hyperplasia areas (circled by green dot lines).  
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Figure 9. Global gene expression profiles of the Lats1/2 double mutants on P0. Heat 
map (A) showed up (red) and down (green) regulated gene expression in Lats1/2 
double deleted livers as compared to wt, among which the most upregulated genes 
were selected and listed in B. The red highlighted genes are the ones that are also 
upregulated in Yap over-expressed mutant livers. GO assay revealed the Lats1/2 
deletion majorly affected liver metabolic function, together with alterations in 
vasculature development.  
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4.4  Biliary hyperplasia and liver stem cell activation in Mst, Sav1 and Lats mutants 
       A striking phenomenon in all three mutants (Mst, Sav1 and Lats) was the 
expansion of BEC cells. In Sav1 mutants, BECs showed expansion at around 8 
months (Figure 10C). In Mst mutants, BEC expansion started from 1 month old and 
dramatically infiltrated into the liver plate at 2 months old (Figure 10B). Both mutant 
livers had inflammatory response represented by increased macrophage population 
(F4/80 positive, Figure 10E and F), suggesting there was chronic hepatic injury. 
However, it is not known whether the BEC expansion is activated by hepatic injury 
(cell non-autonomous) or intrinsic gene deletion (cell autonomous), or both. Similar but 
more dramatic phenomenon was observed in Lats mutants at P0 (Figure 11 E and G), 
suggesting bile duct developmental defects upon Lats deletion.  
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Figure 10. Oval cell activation and inflammatory response in Mst and Sav1 mutants. 
The A6 antibody, a marker for oval and ductal cells stains only ductal cells in wild-type 
tissues (A), but stains both ductal cells and periductal cells in Mst1/2 mutants (B) and 
Sav1 mutants (C). Inflammatory response is revealed by F4/80 staining, a marker for 
macrophages. Both mutants show elevated macrophage population (E and F) [38].  
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Figure 11. BEC hyperplasia in Lats1/2 mutants at P0. Lats1/2 double mutants die from 
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hypoglycemia on P0. (A) In contrast to the even and smooth surface texture of the wild 
type liver, Lats1/2 double deleted liver shows necrotic lesions (A). While BECs are 
rarely visible in wild types by HE staining, many are found surrounding the portal area 
in mutants (C). Consistently, both A6 and CK19 staining reveal expanded population 
of oval/ductal cells in mutants (E and G). 
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       As liver stem/progenitor cells are believed to reside in the BECs and/or periportal 
hepatocyte population [172,173], we used antibody staining to detect whether they 
were activated together with BECs. Although there is no specific liver stem cell marker, 
several antibodies (OC2-1D11, MIC-1c3, A6 and OC-6) that detect a heterogeneous 
population of the immature hepatic cells have been generated [103,174,175,176,177] 
and widely used for detecting immature hepatic cell population. We found liver 
stem/progenitor cell activation in all three mutants (Mst, Sav1 and Lats) using at least 
two of these antibodies (Figure 12, only one antibody staining is shown here for Sav1 
due to poor image quality).  
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Figure 12. Antibody characterization of liver oval cell. (A) The antibodies A6, OC2-
1D11, and MIC1-1c3 stain ductal cells in wild-type (see WT 10X and 40X). At 2 
months old, Mst1/2 mutants have increasing A6, OC2-1D11, and MIC1-1c3 positive 
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cells surrounding the portal area and also infiltrating into liver plates. Sav1 mutants 
also exhibit enhanced A6 labeling at four months of age. Antibody A6 and MIC1-1c3 
recognize a few newly formed ductal cells in E18.5 wt liver. However, more positively 
stained cells clustered and formed ductal structure in Lats1/2 mutants.  All sections are 
counterstained with DAPI.  
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4.5  Yap and Taz are both dominant downstream inhibition targets of Lats 
         Although Lats is a broad governor for cellular homeostasis [53], Yap and Taz are 
the only known proteins inhibited by Lats. In order to know whether Yap and Taz are 
the main in vivo Lats interacting proteins that contribute to Lats mutant phenotypes, we 
performed the rescue experiment by introducing floxed-allele Yap and Taz into the alb-
cre;lats1/2 genetic background. The efficiency of alb-cre mediated Yap and Taz 
deletions was accessed by both mRNA level and protein level (Figure 13A). Results 
showed over 99% deletion of Yap (Figure 13B) and approximately 80% deletion of 
Taz (Figure 13C).  
 
 
 
Figure 13. Yap and Taz deletion efficiencies by alb-cre. (A) Western blot shows 
reduced Taz protein level and almost undetectable Yap protein level in Yap/Taz 
mutants, which are consistent with the mRNA level detected by real-time PCR, shown 
in (B, Yap) and (C, Taz). 
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        Yap is required for bile duct formation and hepatocyte survival, but alb-cre;yap 
mice are still viable and tumor free for more than one year [56], which potentiates the 
outcome of longer lifespan of the alb-cre;lats1/2;yap mice if Yap activation does 
contribute to Lats mutant phenotype. Our results support this speculation by showing 
that the medium survival length of the alb-cre;lats1/2;yap mice was 12 days (Figure 
14), which significantly extended Lats mutants lifespan (P0) by restoring glycogen 
synthesis (Figure 15C). Deleting even one allele of the yap gene significantly rescued 
the Lats mutant phenotype: ductal hyperplasia was reduced (Figure 16) and the 
lifespan was extended with a medium survival length of 5 days (Figure 14). Thus, Yap 
is a main Lats downstream inhibition target in vivo and its activation contributes 
significantly to Lats mutant phenotype. 
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Figure 14. Yap/Taz deletion rescues Lats1/2 mutants in a dose-dependant manner. 
From the survival curve and the median survival length, Yap and Taz show dosage 
effects in rescuing Lats1/2 double mutants neonatal lethality. While Yap appears to be 
a major downstream effecter of Lats1/2 protein as its deletion extends Lats mutants 
lifespan to a great degree, Taz is also indispensable for proper liver function, as Taz 
deletion significantly increases Lats mutant and Lats plus Yap tri-deletion mutants’ life 
spans. 
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Figure 15. Glycogen level comparison in the rescue experiment by PAS staining. (A) 
Glycogen level in wild-type P0 liver. Lats1/2 double mutant have significantly reduced 
the glycogen level (B). By combining Yap deletion, the liver actually shows an 
increased glycogen level (C). The glycogen level is totally normal when combining Yap 
and Taz deletions with Lats1/2 double deletion (D). 
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Figure 16. Deletion of one allele of Yap decreases Lats1/2 double mutants’ ductal 
hyperplasia. In P0 wild type liver, CK19 positive cells are few, surrounding the portal 
vein. In alb-cre;lats1/2 liver, CK19 positive cells show hyperplasia. In alb-
cre;lats1/2;yap/+ liver, the number of CK19 positive cells is between these of the wild-
type and alb-cre;lats1/2; Ductal structural can be seen, although slight hyperplasia still 
exists.  
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        Taz is a paralog of Yap and also biochemically phosphorylated and inhibited by 
Lats. So far, there has not been any report about Taz function in the liver. In 
characterizing of alb-cre;yap;taz liver, we found that further Taz deletion did not 
significantly elevate the mutant phenotype of the Yap deletion. Similar phenotypes 
showing increased hepatocyte turnover (Figure 17) and defects in bile duct 
development were found (Figure 18). The alb-cre;yap;taz mice were viable and tumor 
free up to 1 year old. As with Yap, to test whether Taz is a down-stream target of Lats 
and contributes to Lats mutant phenotype, Taz deletion was introduced into a Lats 
mutant genetic background. The significantly extended median survival time (5 days) 
of the alb-cre;lats1/2;taz mutants (Figure 14) revealed that Taz is also a main Lats 
downstream inhibition target and its activation contributes to Lats mutant phenotype.  
        Moreover, according to the survival curve (Figure 14), the mutants’ median 
survival time was extended as one more allele of Taz and Yap were deleted, 
suggesting that Taz and Yap rescued Lats mutant lethal phenotype in a dosage-
dependent manner on the basis of a single allele. Furthermore, synergistic effect 
between Yap and Taz may exist as Yap and Taz double deletion showed the most 
dramatic rescue effeciency, which was significantly different from those of either Yap 
or Taz deletion.  
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Figure 17. Increased hepatocyte turnover in Yap/Taz double deleted liver. The mutant 
liver is larger (B) as compared to wild type (A). The mutants’ mean liver/body weight 
ratio is slightly higher than wild type (C), which is due to continuous hepatic 
proliferation (E and F). In addition, the mutant liver shows increased inflammation and 
engulfment of hepatocytes by macrophages (H). Mutant hepatocyte injury is 
represented by increased AST and ALT level (I). 
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Figure 18. Bile duct malformation in Yap/Taz double deleted liver. Mice with liver-
specific deletion of Yap/Taz are viable, however the liver has a larger gallbladder and 
develops adenomas at around one year of age (B). Adenoma is a kind of benign tumor 
that characterized by loss of bile ducts. Though in mutants some areas still develop 
bile ducts, they are malformed as shown in HE staining (D) and CK19 staining (G, 
arrowed). C and F show the morphology of normal bile ducts in wild type. 
 
 
 
 80 
4.6. Yap increase/activation correlates with BEC expansion in Lats mutant. 
        Interesting questions have arisen regarding the cause of biliary hyperplasia in 
Mst, Sav1 and Lats mutants and whether it is cell autonomous or non-autonomous. As 
Mst (facilitated by Sav1) inhibits Yap/Taz through Lats, it is very likely that the 
activated Yap activity is responsible for the biliary hyperplasia in all three mutants. We 
further investigated the mechanism of biliary hyperplasia in the Lats mutant. Due to the 
fact that Lats functions downstream of Mst, and also because Lats mutants show the 
most dramatic biliary hyperplasia, their use will facilitate the detection of abnormalities.  
         The intrahepatic bile duct (IHBD) plates form around E14.5 [178,179]. Therefore, 
mutant and wild type livers from E15.5 to E18.5 were collected to investigate the 
progress of biliary hyperplasia. Double staining of CK19 and Ki67 revealed that 
elevated BEC proliferation started from E16.5 and became dramatic at E17.5 (Figure 
19). Interestingly, Yap was dominantly expressed in BEC-like cells and increased Yap-
positive periportal cell population also starting from E16.5 and further elevated 
afterwards (Figure 20). The correlation between these two observations supports our 
speculation that activated Yap is responsible for biliary hyperplasia. Thus, cell 
autonomous proliferation contributes, at least partially, to the biliary hyperplasia in all 
three mutants. Furthermore, Yap may be a new BEC marker, whose level/activity 
regulates bile duct development. Double staining of Yap with a known BEC marker 
(e.g. CK19 and Sox9) is required to confirm this theory.  
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Figure 19. BEC proliferation in Lats mutants starting from E17.5. (By Kilang Yanger, 
University of Pennsylvania) 
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Figure 20. Yap positive cells expand in Lats mutant. Yap antibody positively stains bile 
ductal-like cells in wild-type livers (A, C and E). Yap positive cells in Lats1/2 double 
mutants are dysplasic and show progressive hyperplasia, and their nuclei are 
pleomorphic (B, D and F).  
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4.7 Notch signaling is activated in Lats mutant periportal area 
        We further investigated whether the dysregulation of the Hippo pathway has 
impact on classic signaling pathways that are essential for bile duct development. As 
Jagged1 gene expression is significantly increased in both Lats deleted liver (Figure 
9) and Yap overexpression liver [34], Notch signaling becomes a promising target 
candidate for our investigation. By double staining of Jagged1 and CK19, a close 
association between Jagged1 positive cells and expanding CK19 positive cells was 
revealed. Moreover, known Notch signaling downstream gene targets (Hes1 and Ostp) 
were activated surrounding the portal area with biliary hyperplasia (Figure 21). These 
results revealed that Notch signaling was elevated upon Lats deletion in the portal 
region, and thus contributed to biliary hyperplasia by enhancing BEC-fate 
determination and promoting bile duct tubular morphogenesis.   
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Figure 21. Notch signaling activation in the periportal area of E18.5 Lats mutants. (By 
Kilang Yanger, University of Pennsylvania) 
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4.8  Yap and Taz are activated during liver regeneration 
        Because Yap and Taz are nuclear effectors of the Hippo pathway, their activities 
can manifest Hippo pathway activity. Yap and Taz phosphorylation and protein levels 
were analyzed during liver regeneration as indicators of potential correlation between 
Hippo pathway activity and liver re-growth.  
        To cover all three liver regeneration phases, six time points were chosen for 
protein analysis: 0h (hour), 6h, 24h, 48h, 72h and 7 days. Western blot analysis 
showed a correlation between Taz activity and regeneration progress: nuclear 
unphosphorylated Taz increased in the priming and proliferative phases (evidenced by 
decreased cytoplasmic phospho-Taz and increased total Taz, Figure 22A), and 
decreased in the termination phase (evidenced by increased cytoplasmic phospho-Taz 
and decreased total Taz). However, phospho-Yap and total Yap changed in the same 
direction, therefore we were unable to determine the coupling between nuclear 
unphosphorylated Yap and liver regeneration based on total protein analysis (Figure 
22B). For this reason, we further used nuclei-cytoplasm protein extracts to detect the 
active form of Yap (unphosphorylated) in the nuclei. Results showed a slight increase 
of nuclear Yap levels during the proliferative phase (Figure 22C), suggesting that Yap 
was also activated. To exclude any artificial results from the surgery procedure, 
pseudo-surgery (sham) were carried out and mice were sacrificed at exactly the same 
time points with that of the PHx mice. Phospho-Yap, P21 and PCNA protein levels 
were checked, and the results showed no change along all the time points that tested, 
implying the surgical procedure does not affect the proteins’ activities or levels (Figure 
22D).  
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Figure 22. Yap and Taz activities during normal liver regeneration. During 
regeneration, Taz phosphorylation is decreased while its total protein level is 
increased (A). Yap phosphorylation is decreased at 6h after PH, however increases 
afterwards. The total Yap amount shows a similar trend during regeneration (B). 
Further nuclear and cytoplasmic localization examination show increased Yap nuclei 
localization along regeneration (C). Yap phosphorylation, PCNA, and P21 expressions 
are not altered in pseudo-surgery (sham) group (D). 
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4.9  Yap/Taz null and Mst1/2 null livers show impaired regeneration 
        In order to further investigate whether Yap/Taz is required and sufficient to 
promote liver regeneration, Yap/Taz deletion (alb-cre;yap/taz) and Yap/Taz activation 
(alb-cre;mst1/2) mice were subjected to PH. To reduce the original liver size variation 
of the Mst1/2 mutant, PH was performed in young mice (5- to 6-week old). According 
to our previous report, Mst1/2 mutant liver size variation at 1 month is much less than 
at 2 months [38].  
        Re-growth percentage and hepatocyte proliferation were accessed as parameters 
for liver regeneration ability. While wild-type livers could fully (100%) re-grow back to 
their original sizes, both Yap/Taz and Mst1/2 mutants re-grew to approximately 70% of 
their original sizes (Figure 23A). Decreased hepatocyte proliferation was likely the 
main reason according to BrdU incorporation assay (Figure 23B). As Yap and Taz are 
the main effecters of Hippo signaling and their pro-proliferation functions are the 
theoretical basis for the hypothesis that Hippo pathway regulates organ size, the 70% 
regeneration ability of the Yap/Taz null liver suggests that the Hippo pathway is not 
critically required for liver regeneration. The impaired regeneration is possibly due to 
the disease effect from early embryonic deletion of Yap/Taz. For the same reason, it 
remains unknown whether activated Yap/Taz (Mst null) can promote the liver to a 
larger setting point. It should be tested in a way that allows avoidance of the disease 
effect of Mst by deleting the genes prior to PH surgery, possibly, by introducing cre-
recombinase adenovirus through tail-vein injection. From the fact that the liver can still 
regenerate without Yap and Taz, it can be concluded that Hippo signaling is not a sole 
 88 
determinant for liver regeneration, or for liver size setting point. Another interactive 
network must compensate the Hippo pathway’s role in liver regeneration. 
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Figure 23. Both Mst1/2 double mutants and Yap/Taz double mutants can regenerate 
to approximately 70% of their original sizes. (A). Neither mutants’ hepatocytes can fully 
proliferate responding to regeneration signals. Mst1/2 mutants have significantly 
retarded hepatocytes proliferation at the peaking time point (2 days after PH). The 
represented BrdU staining of samples of day-2 after PH shows decreased Yap/Taz 
mutant hepatocyte proliferation (D), as well as decreased Mst1/2 mutant hepatocyte 
proliferation (E), as compared to normal hepatocyte proliferation(C). 
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4.10  Hippo signaling regulates the timing of hepatocyte proliferation 
        Liver regeneration is indeed a process of synchronized hepatocyte cell-cycle 
progression [166,180]. Although many genes’ loss-of-function do not completely inhibit 
liver regeneration, they often affect the timing of hepatocyte cell-cycle progression 
[131,164,181,182]. We therefore also investigated the timing of the Yap/Taz-null and 
Mst-null hepatocyte cell-cycle progression, specifically, the timing of the cell-cycle 
reentry. 
        A critical step of cell cycle progression is cell cycle initiation, in which cells pass 
through the G1 phase cell cycle checkpoint and enter the DNA-synthesizing S phase. 
Yap/Taz double mutants had higher Cyclin D1, P21 and PCNA baseline levels before 
PH (0h), which were likely due to cell non-autonomous compensatory growth. After 
PH, however, a synchronized but delayed expression pattern was seen (Figure 24A). 
Specifically, Cyclin D1 expression peaked at 72 h after PH in mutants, which was 2 
days later than the wild-type littermates. The timing of STAT3 signaling (known to be a 
master regulator for the timing of hepatocyte cell-cycle reentry [183]) was unchanged 
although enhanced at the 24h time point (Figure 25A), suggesting the Yap/Taz 
deletion may affect the downstream of STAT3 signaling and caused the delay of 
CyclinD1 expression.  
        The same analysis was performed in Mst1/2 double mutants. Instead of delayed 
cell cycle re-entry, Mst null hepatocytes showed a persistent proliferation pattern 
(Figure 24B). Similar to Yap/Taz null hepatocytes, the timing of the STAT3 activity in 
Mst null hepatocytes was unchanged, but slightly elevated at the 24h time point 
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(Figure 25B), suggesting that the Mst deletion also caused effects downstream of 
STAT3 signaling and disrupted the synchronization of cell cycle re-entry.  
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Figure 24. Cell cycle progression is delayed during Yap/Taz double mutants’ 
regeneration. (A), and advanced during Mst1/2 double mutants’ regeneration (B).  
Yap/Taz double mutants (A) have higher Cyclin D1, PCNA and P21 basal level before 
regeneration (0h). Responding to the regeneration signal, Cyclin D1 in mutants shows 
maximal expression at 72 h, which is 2 days later than the wild-type littermates’ (24h). 
Peaking expression of PCNA in mutants is still at 48h, but the level is lower than that 
of wild type. Peaking expression of P21 in Yap/Taz mutants is at 72h, which is one-
day delayed as compared to the wild-type littermates. In Mst1/2 double mutants (B), 
the basal levels of PCNA and Cyclin D1 are higher, however, P21 was lower as 
compared with wild-type littermates’. Cyclin D1 peak level is at 24h in Mst1/2 mutants, 
but occurs at 48h in the wild type littermates. PCNA level increases immediately after 
PH and remains persistently high afterwards, even at 7d after PH. P21’s peak time in 
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mutants is the same as in the wild-type littermate’s (48h after PH); however, the 
protein level is higher as compared to wild-type littermates. Actin is used to show 
relatively equal loading among samples. 
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Figure 25. STAT3 activity during regeneration. In wild type liver regeneration, STAT3 
peaks at 24 h after PH. In both Yap/Taz and Mst1/2 double mutants, STAT3 still peaks 
at 24h time point, but the levels are higher than at the same time point in wild types.  
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CHAPTER 5:  DISCUSSION  
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        Our study is among the first ones that address the Hippo pathway function in a 
mammalian system. We have shown that although the Hippo pathway functions 
ubiquitously in regulating tissue homeostasis, it has certain tissue specificity in the 
liver. Our work has addressed how the main components function individually in the 
live. Results show that the Hippo pathway is not only involved in maintaining liver 
homeostasis, but is also required for the liver development. Furthermore, we found 
evidence that the Hippo pathway interacts with Notch signaling in regulating the biliary 
system. However, in terms of the organ size control function, it is not the sole 
determinant of the organ size setting point, but does influence the timing of hepatocyte 
cell cycle progression. As tumor development is often associated with disturbances of 
the cell cycle regulation, the Hippo pathway may suppress liver tumor development 
through surveilling the hepatocyte cell cycle progression. Our study is significant in 
advancing understanding of the tumor suppression mechanism and in helping to 
develop potential therapeutic approaches for liver cancer.      
5.1  Mst in liver tumor suppression 
        Before Mst was recognized as the “Hpo” kinase in the Hippo pathway, it was 
known for its role in mediating the apoptosis induced by cellular stress 
[184,185,186,187]. Except for its ability to form complexes with members of the Rassf 
family [52,188], which are known to be tumor suppressors, no direct evidence 
supported Mst being a tumor suppressor. When its Drosophila ortholog, the Hpo 
kinase, was characterized, new insights into the role of the Hippo pathway as a 
suppressor of tissue growth were gained. Mst was hypothesized to be a tumor 
suppressor in the mammals. To test this hypothesis, several groups, including our lab, 
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generated Mst1 and Mst2 conditional knockout mice and analyzed their phenotypes 
[37,38,41]. While the other groups studied Mst function only in the liver as inspired by 
the first report about Yap over-expression in liver resulting in HCC ([34]), we tested 
Mst function in several tissues by using both tissue specific (villin-cre) and widely-
active cre (MMTV-cre, and Caggs-cre) lines. We found that Mst most likely has a 
ubiquitous function in tissue homeostasis, but also has certain tissue specific functions 
in the liver. The underlying mechanism is yet not known.   
         Different research groups consistently reported that HCC developed as a 
consequence of Mst deletion, suggesting that the Mst is an important liver tumor 
suppressor. Before tumor development, Mst null livers were bigger than normal due to 
increased hepatocyte proliferation and suppressed apoptosis [38,41,189], a feature 
reminiscent of the Hpo mutant phenotype in Drosophila. Yap activation was also 
consistently observed in the Mst null liver, which supported our hypothesis that the 
mammalian Hippo pathway is a tumor suppressor pathway. However, several 
inconsistencies exist between the Mst null livers generated by different labs.  First of 
all, there is controversy of whether Lats mediates Yap inhibition by Mst: we found that 
the Lats phosphorylation was depleted in the Mst null hepatocytes [38]; another group 
claimed that Lats phosphorylation was unaffected upon Mst deletion [189]. The reason 
for this disagreement may be due to different cell types used in each experiment. We 
used the enriched hepatocytes, and the other group used Mst null MEFs. Whether Mst 
inhibits Yap through different mediators in different tissue contexts or cell types may 
be addressed by testing in other tissue types or in different cell lines. 
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       Another disparity is in the histology results of Mst-null livers generated by different 
labs. Dr. Yingzi Yang’s group and our group observed systematically inflammatory 
response in the Mst deleted liver resulting in infiltration of the macrophages together 
with liver progenitor cells into the periportal area [38,41]. This phenotype was not 
obvious in the Mst-null liver mouse model generated by Dr. Nabeel Bardeesy’s lab 
[189]. In addition, mutant liver with systematic inflammatory response developed 
tumors in multifoci or a diffuse fashion [38,41], while the one without obvious 
inflammatory response developed tumor in unifoci [189]. By looking into the way these 
mutants were generated, we believe that the genetic differences contribute to these 
phenotypic inconsistencies. Dr. Yingzi Yang’s group and our group used alb-cre to 
deletion both Mst1 and Mst2 at the same time (alb-cre;mst1/2fl/fl), while Dr. Nabeel 
Bardeesy’s group deleted Mst1 in the germline and later deleted Mst2 in liver by alb-
cre (alb-cre;mst1∆/∆;mst2∆/fl). Mst1 is an important regulator of T-cell maturation, 
adhesion and migration [190,191]. Under pathological conditions, such as bacterial 
and viral infection, liver immune cells including küpffer cells, NK cells, NKT cells, and 
T-cells are activated in a positive feedback loop to protect the host from bacterial and 
viral infections [192]. As the fetal liver is a major site of development of the immune 
system [193], germline deletion of the Mst1 may impair the development of T-cells, 
disrupt the immune response loop and disable the inflammatory response that would 
occur when Mst2 is further deleted by alb-cre. Persistent inflammation is the main 
cause of liver cirrhosis and subsequent development of HCC (reviewed in [194,195]). 
The systematic inflammatory response in the alb-cre; mst1/2fl/fl mice is very likely the 
main reason for the early development of multifocal cancerous lesions, which 
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accelerates the liver disease progression from the genetic alteration (i.e. Mst deletion). 
As a consequence, alb-cre;mst1/2fl/fl mice have a shorter lifespan (6-7 months) [38,41] 
compared with the alb-cre;mst1∆/∆;mst2∆/fl mice (12-15 months) [189].  
         While the detailed mechanism of inflammatory response and tumor initiation in 
Mst-null liver is still not clear, there are several possibilities may apply. One is 
epigenetic alteration caused by Mst gene deletion. There are accumulating evidence 
that epigenetic mechanisms are essential for both normal development and cellular 
homeostasis. Global changes in the epigenetic landscape are a hallmark of cancer 
[196]. Mst can indirectly affect gene expression through inhibiting Yap, but also can 
directly regulate gene expression through interacting with chromatin. Over-expression 
of Mst can induce chromatin condensation through phosphorylation of histon H2B and 
H2AX [197,198] [199] and may thus regulate gene expression at the epigenetic level. 
Another possibility is the accumulation of DNA damage during mutant hepatocyte 
proliferation. One of Mst phosphorylation targets, the γH2AX, plays an important role in 
DNA double-strand break (DSB) repair [200,201,202] and has become a biomarker for 
measuring DNA damage [203]. Deletion of Mst may impair the DNA-repair mechanism 
through inhibiting γH2AX, resulting in DNA damage accumulation. DNA damage 
contributes to cell necrosis and release of dead cell cytosol, which triggers the 
inflammatory reaction and promotes tumorigenesis. A good example is the HCC 
induction by the carcinogen diethylnitrosamine (DEN) [204,205].  
        In conclusion, Mst is a liver tumor suppressor. It suppresses liver tumor formation 
by maintaining hepatocyte quiescence and liver homeostasis. It may provide a good 
model for studying inflammatory response and testing the corresponding treatments. 
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5.2  Lats in liver development 
        Lats is believed to be a broad governor of cellular homeostasis because of its 
involvement in many important cellular processes, including proliferation, apoptosis, 
senescence, transformation, and migration (reviewed in [53]). At the molecular level, 
multiple domains enable diverse functions such as protein-protein interaction and 
phosphorylation. Therefore, although Yap and Taz are so far the only known 
substrates of Lats, multiple substrates are predicted and there is ongoing research that 
aims to identify other Lats substrates by using consensus phosphorylation sequence 
of Lats. However, our in vivo genetic analysis about the relationship between Yap/Taz 
and Lats revealed that Yap and Taz are the main substrates of Lats (Figure 14). This 
close relationship between Yap/Taz and Lats may have liver-tissue specificity since 
Lats specific transcriptional targets identified in Hela cells suggest that the Lats 
functions through multiple pathways [53,206].  
        Although Lats contributes to many cellular events, how it functions in vivo and 
contributes to organ function is not known. Our work is the first one to study the Lats 
function in vivo by double deletion of the two Lats paralogs (Lats1 and Lats2). We 
found that Lats may participate in governing the cholangiocyte-lineage formation 
through restricting both Yap activity and Yap protein levels. Through microarray 
analysis and immunostaining, we found that upon Lats deletion, the Notch signaling 
required for biliary differentiation and morphogenesis [81,82,83,87,88] was activated 
(Figure 21) while Tbx3, which globally inhibits the biliary differentiation [207], was 
suppressed. These changes may thus switch a normal liver developmental 
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environment to the one that favors the biliary development. Although hepatocytes still 
developed, microarray data on postnatal day 0 liver showed a global decrease in all 
most all the hepatocyte functions (Figure 9). This may be a result of immature 
hepatocyte development due to Lats deletion.  
        The mechanism of Lats control of hepatic lineage differentiation is yet unknown. 
One of the possible mechanisms is through interaction with the Notch signaling 
pathway. Elevation of Jagged1 gene expression in both Lats-deletion mutants and 
Yap-over-expression mutants suggests that Jagged1 may be a direct gene target of 
Yap. If so, Lats-Yap(/Taz) may affect the bile duct development by regulating the 
Jagged1 expression and its downstream Notching signaling. In addition, Sox9 is also 
up regulated in both Lats deficient mutants and Yap-over-expression mutants, which 
suggests that Sox9 could be a direct target gene of Yap. Sox9 is a BEC marker 
regulated by Notch signaling during biliary morphogenesis [77,82]. These results point 
towards a certain interactive relationship between the Hippo pathway and the Notch 
signaling. Diagram 5 shows the possible relationship between the two pathways 
based on the assumption that jagged1 and sox9 are direct gene targets of Yap. How 
the two pathways together regulate bile duct development is particularly interesting 
because it may help advance understanding of the mechanism of human Alaggille 
syndrome (AGS). AGS is a genetic disorder characterized by abnormalities in liver, 
heart, eye, skeletal, craniofacial and kidney [208]. It is caused by a null mutation in 
Jagged1. In liver, Jagged1 deletion results in bile duct paucity and chronic cholestasis 
[84,86], which is one of the life-threatening symptoms in AGS patients. Obviously, 
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Jagged1 plays an important role in bile duct development, and understanding its 
regulation will be of course important for developing the treatments for AGS patients. 
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Diagram 5. Potential Hippo pathway function in bile duct development. The Hippo 
pathway inhibits Yap/Taz through phosphorylation. Unphosphorylated Yap (and likely 
Taz too) is likely to associate with some unknown transcription factor, and activating 
jagged1 and sox9 transcription, which contributes to the activation of Notch signaling 
and subsequent bile duct development. The relationships marked by dashed arrow 
lines need to be experimentally confirmed.  
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       A major conclusion from the above discussion of the phenotypes of Mst and Lats 
mutants is that, Mst is important for the liver homeostasis because of its ability in 
reducing the inflammatory response; while Lats more closely interacts with Yap and 
regulates cellular behavior through controlling the hepatic transcription profile. 
Although the Mst-Lats-Yap linear kinase cascade is still present, the function of the 
mammalian Hippo pathway is complicated by the diverse individual functions of its 
components. Moreover, existence of multiple versions of Hippo pathway proteins may 
complicate the pathway further by adding other regulatory inputs. There is emerging 
evidence that Mst3/4 interacts with Ndr1/2 (Lats family proteins) in regulating Yap 
activity [209,210]. Despite the complexity of the pathway’s upstream regulation, Yap 
and Taz are so far the only known nuclear effecters of Hippo signaling. The significant 
rescue effect of Yap/Taz deletion on Lats mutants (Figure 14) and Mst mutants (by 
other lab members) clearly suggested that Yap/Taz is the key element of the Hippo 
pathway in regulating liver homeostasis. As Yap activation is highly associate with the 
poorly differentiated HCC and a low patient survival rate [51], Yap may be a promising 
therapeutic target for HCC treatment.   
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5.3  The Hippo pathway in liver size control 
        How organ size is controlled is a fundamental biological question. The prevailing 
opinion is that organ size is regulated by an intrinsic “total mass checkpoint” 
mechanism (reviewed in [211]). This mechanism ensures that organs maintain an 
inherited size through modulating the number and the size of their constituting cells. 
Classic Drosophila genetic screening for genes involved in this mechanism has 
identified the Insulin-PI3K-Akt signaling pathway and dTOR (Drosophila target of 
rapamycin) pathway as playing central roles. The two pathways merge at S6K, which 
regulates a cell’s overall mRNA transcription and thus affects cell growth/size 
(reviewed in [211,212,213]). In contrast, the Hippo pathway appears to mainly affect 
cell proliferation and survival, and thus regulates organ size via the number of cells.  
        Liver is known for its unique ability of regeneration, by which it is able to keep a 
constant size through a checkpoint, or setting point. The regeneration process is 
strictly controlled by signaling networks with functionally redundant intracellular 
components, and thus loss of an individual gene rarely leads to complete inhibition of 
liver regeneration. Therefore it is not surprising to see that Yap/Taz null liver still can 
regenerate to about 70%. Actually, there is speculation that Yap/Taz null liver may be 
able to regenerate 100% of its original size if Yap/Taz is deleted right before surgery, 
which prevents the disease effect from embryonic gene deletion. The impaired 
regeneration in both Yap/Taz-null and Mst-null livers may be a result of this disease 
effect. To avoid the disease effect, recombinant adenovirus-cre recombinase can be 
introduced into liver through tail-vain injection right before surgery. However this 
technique modification will not change our current conclusion that the Hippo signaling 
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is not a critical determinant for liver size control, because the deletion of Yap/Taz does 
not dramatically inhibit liver re-growth. 
          Although individual component deletion rarely inhibits liver regeneration, it often 
impairs hepatocyte proliferation [183,214] or delays the timing of regeneration phases 
[181,182,215,216]. In our study, Mst null liver had a disrupted synchronization of 
hepatocyte cell cycle progression, while Yap/Taz null liver showed a delayed 
hepatocyte cell cycle re-entry. Because Mst-null liver and Yap/Taz-null liver are 
supposed to have opposite effects on Yap/Taz activity, and Yap/Taz is known to 
promote cell proliferation, the difference between the two cell-cycle progression 
patterns suggests a dominant role of Yap/Taz in promoting cell cycle re-entry, i.e. the 
G1/S transition. It is likely that the activated Yap/Taz (in Mst-null liver) overrides the 
normal regenerative rhythm and activates the G1/S transition regardless of the normal 
timing; whereas in the absence of Yap/Taz (Yap/Taz-null liver), the intrinsic 
regenerative mechanism may lack the proliferative inducing signal at the beginning, 
but this lacking can be eventually compensated for by other signals and therefore the 
regeneration rhythm appears to be delayed. The point here is that although Yap/Taz 
regulates cell cycle re-entry, there are compensatory mechanisms during liver 
regeneration that substitute when the Yap/Taz function is not available. Our finding 
complies with the general thinking that liver regeneration is well controlled by signaling 
networks with functionally redundant components, and loss of an individual component 
rarely leads to complete inhibition of liver regeneration. 
        Emerging evidence suggests that the Hippo pathway may interact with the mTOR 
pathway and the PI3K/Akt pathway, both of which are known to be important for liver 
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regeneration. Evidences for the interaction between the Hippo and mTOR pathways 
includes: 1) deletion of Mer/NF2 results in activation of mTORC1 [217,218], which is 
an mTOR kinase inhibitor complex; 2) loss of Mst activates mTORC1 [189] and affects 
mTORC2 downstream signaling [219]; and 3) Yap regulates IGF-1, which is a known 
activator of the mTOR pathway [220]. Furthermore, the transcription factor Myc has 
been identified as a gene target of Yki [221,222], and it has also been shown to affect 
the transcription of TSC2 by binding to its promoter [223]. It has been reported that 
activation of the TOR pathway leads to increased cell growth and cell cycle re-entry 
[224,225,226]. In a liver subjected to partial hepatectomy, mTOR pathway appears to 
regulate liver regeneration by modulating cell growth and proliferation in response to 
the energy demands of the remaining liver [227,228,229]. The interaction between the 
Hippo and PI3K/Akt pathways is more direct: Akt directly phosphorylates Yap to 
induce interaction with 14-3-3 and result in functional inhibition [230]. Akt also 
indirectly activates mTOR pathway by regulating cellular ATP levels and AMPK activity 
[231,232]. The three pathways form a network and may compensate for each other in 
regulating liver regeneration and liver size. In the Yap/Taz null liver, PI3K/Akt may 
elevate mTOR pathway activity in response to insufficient cell proliferation, resulting in 
liver mass re-growth with a delayed timing of cell cycle progression. The diagram 
below illustrates the possible regulatory mechanism of liver regeneration by the three 
pathways (Diagram 6).  
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Diagram 6. Both Akt and Mst can inhibit either mTORC or Yap/Taz. mTORC inhibits 
mTOR kinase, which otherwise promote cell growth and cell proliferation. Akt and Mst 
control both mTOR activity and Yap/Taz activity, and may thus modulate the two 
pathways to achieve liver size control.  
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CHAPTER 5: FUTURE STUDIES 
 110
 
        In mouse, Yap over-expression drives liver tumor development [34]. In human 
liver cancer patients, Yap hyper-activation is correlated with tumor malignancy and low 
patient survival rate [51]. Study Yap function in liver is therefore important for 
understanding liver cancer initiation, and may help to develop strategies for liver 
cancer diagnosis and treatments.  
       Yap is a transcription cofactor that regulates target gene expression by binding to 
transcription factors. Domain analysis revealed that Yap has the potential of binding to 
a variety of transcription factors via its WW-domain [57,233]. Several Yap-interacting 
transcription factors have been reported [65,66,230]. However, their interactions with 
Yap have not been tested in vivo, nor do they give a systematic view about Yap 
function in liver. Microarray data of the Lats deficient liver and the Yap over-expression 
liver provide an overview on the gene population affected by Yap, but the ones directly 
regulated by Yap and contributing to liver homeostasis are not known. To address the 
above questions, it is important to find out the transcription factors that Yap directly 
associated with in liver.  
       Functional protein arrays are emerging as a new tool for studying protein-protein 
interaction in a large scale (reviewed in [234]) and can be used to identify the Yap-
binding transcription factors. Potential candidates should be verified by IP (immuno-
precipitation) assay and their functional contribution to Yap can be tested in cell culture 
system or mouse. Below shows an example of studying the interaction between Yap 
and one of its potential interacting transcription factors in regulating bile duct 
development.   
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       In our study, Yap up-regulation correlates with biliary hyperplasia and decreased 
hepatocyte function, suggesting a possible mechanism that Yap activates a gene 
profile in favor of BEC differentiation and bile duct development. If this is true, then the 
Yap function is opposite to the transcription factor C/EBP (CCAAT/enhancer-binding 
protein), specifically, C/EBPα, which plays an important role in promoting hepatocyte 
differentiation and inhibiting biliary cell differentiation [235,236,237,238]. Analysis of 
the protein domains of C/EBPα and Yap predicts a possible physical interaction 
between the two. This suggests a role for Yap in promoting bile duct development 
through inhibiting C/EBPα (Diagram 7). 
       C/EBP is a leucine zipper transcription factor widely expressed but primarily in 
tissues known to metabolize lipid and cholesterol-related compounds at uncommonly 
high rates, such as liver, fat and intestine [239]. Six isoforms of the C/EBP have been 
isolated (C/EBPα to ς), among which the C/EBPα is the first one cloned [239,240] and 
has been extensively studied. C/EBPα is detected only in differentiated tissues 
[239,241], and therefore being implicated in regulating the terminal differentiation of 
mammalian cells, including hepatocytes. C/EBPα is expressed at high levels in 
hepatocytes, where it regulates a variety of hepatocyte-specific genes, such as serum 
albumin [242], haptoglobin [243], phosphoenolpyruvate carboxykinase (GTP) (PEPCK) 
[244], etc. Its importance for hepatocyte function is also reflected by its inhibitory effect 
on biliary cell differentiation [236,237]. Suppression of C/EBPα expression increases 
Hnf6 and Hnf1b, two important transcription factors in biliary cell differentiation, 
[245,246]. Over-expression of C/EBPα can even cause trans-differentiation of 
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pancreatic cells to hepatocytes [247], demonstrating its essential role in hepatocyte 
fate determination.  
 
 
 
 
Diagram 7  Hypothesized Yap function in biliary cell differentiation. (A) With low level 
or no Yap expression, C/EBPα activates genes essential for hepatocyte differentiation 
while suppressing BEC essential genes. (B) In the presence of Yap, C/EBPα 
transcriptional activity is suppressed, leading to a switch of the downstream gene 
expression pattern from hepatocyte differentiation to BEC differentiation.  
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        We hypothesized that Yap promotes bile duct development through inhibiting 
C/EBPα (Diagram 7). To test this hypothesis, three questions can be investigated. 
First, does Yap over-expression suppress the C/EBPα activating genes, such as 
albumin, hepatoglobin, and urea cycle enzymes, and at the same time induce Hnf6 
and Hnf1b expression (Diagram 7)? Second, does Yap deletion block biliary cell 
differentiation? Third, would a C/EBPα dominant mutation antagonize the biliary 
differentiation promoted by Yap over-expression?  
       To reduce cell non-autonomous effects, assays and tests can be carried out in a 
primary hepatoblast culture system. Hepatocyte differentiation can be induced by 
Oncostatin M (OSM) [248,249,250] and the effect of Yap and C/EBPα interaction on 
regulating hepatic differentiation can be accessed by detecting the expressions of both 
hepatocyte and biliary cell-specific genes (Diagram 6). To test the direct inhibition 
effect of Yap on C/EBPα, mutations can be introduced into the PPXY motif (where it 
binds to Yap) of C/EBPα through gene targeting. This mutated form of C/EBPα should 
be unaffected by Yap and therefore promoting hepatocyte differentiation regardless of 
Yap activity. The hypothesized Yap- C/EBPα interaction in regulating hepatoblast 
differentiation can be further tested in vivo through transplantation into the testes of 
SCID (severe combined immune deficient) male mice. The testes of SCID male mice 
provide an ideal in vivo environment for cell survival and growth. When liver fragments 
are transplanted into the testes of SCID mice, normal hepatoblasts can construct 
mature hepatic tissue accompanied by biliary cell differentiation, whereas the C/EBPα 
deficient hepatoblasts only give rise to biliary cells [237]. If Yap do regulate biliary cell 
differentiation through inhibiting C/EBPα, then Yap over-expression will promote biliary 
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cell differentiation but loose this effect on the C/EBPα deficient or mutated (at Yap 
binding residues) hepatoblasts.  
        This study will identify the Yap-binding transcription factors and its directly 
regulating genes in a systematical manner. The results may help to understand the 
mechanisms of tumor development driven by Yap activation.  
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APPENDIX 
 
Appendix 1. Liver phenotypes of the mutant mice from the rescue experiment. (A) P0, 
representative lats1/2 double deleted liver and the wild-type liver of the same 
developmental stage. P6, representative alb-cre;lats1/2;taz liver and the wild-type 
littermate’s liver. P28, representative alb-cre;lats1/2;yap liver and the wild-type 
littermate’s liver. 5 months, representative alb-cre;lats1/2;yap/taz liver and the wild-
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type littermate’s liver. (B) HE staining on liver tissues from the rescue experiment. All 
of them show ductal-like expansion. Mice with Lats1/2 and Taz deletions die around 
P5-P6 and show the most dramatic ductal hyperplasia. With Lats1/2 and Yaz 
deletions, at P11, mutant livers have normal hepatocytes however the liver plates are 
disrupted by clumps of unrecognized cells. Livers with Lats1/2 and Yap/Taz deletions 
have normal hepatocytes at 2-months age; however there are still clumps of 
unrecognized cells penetrating the liver plates.  
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Appendix 2.  Decreased phospho-Lats1 in Yap/Taz double mutants. During normal 
liver regeneration, phosphorylation of Lats1 decreases at 6h and 48h after PH, and 
increases at 72h after PH. Total Lats1 gradiently increases in the first three days of 
regeneration and returns to normal level at 7d after PH. During Yap/Taz double 
mutants’ regeneration, the total Lats1 shows similar pattern as in normal liver; 
however, the phosphorylation of Lats1 is significantly decreased. 
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Appendix 3. Yap and Taz activities during Mst1/2 double mutants’ regeneration. 
Western blot shows that during normal liver regeneration, the phosphorylation of Yap 
and Taz are differentially regulated; however they appear to be similarly regulated 
during Mst1/2 double mutants’ regeneration. The total protein levels of both Yap and 
Taz are increased in Mst1/2 mutant. Actin is used as protein loading controls.  
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